<SEC-DOCUMENT>0001144204-17-010284.txt : 20170222
<SEC-HEADER>0001144204-17-010284.hdr.sgml : 20170222
<ACCEPTANCE-DATETIME>20170222060549
ACCESSION NUMBER:		0001144204-17-010284
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20170221
FILED AS OF DATE:		20170222
DATE AS OF CHANGE:		20170222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		17626987

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		5 HACHAROSHET ST.
		CITY:			RAANANA
		STATE:			L3
		ZIP:			4365603
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v460062_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of February, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>001-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals Ltd.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5 Hacharoshet St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PO Box 4423</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Raanana 4365603, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2017,
XTL Biopharmaceuticals, Ltd. (the &ldquo;Company&rdquo;) entered into securities purchase agreements (the &ldquo;Purchase Agreement&rdquo;)
with certain institutional investors providing for the issuance of an aggregate of 1,000,000 American Depositary Shares (the &ldquo;ADSs&rdquo;)
in a registered direct offering at $2.50 per ADS for aggregate gross proceeds of $2,500,000. The offering is expected to close
on or about February 23, 2017, subject to the satisfaction of customary closing conditions. In addition, under the Purchase Agreements,
the investors received unregistered warrants to purchase 1,000,000 ADSs. The warrants may be exercised after six months from issuance
and terminate five and a half years from issuance and have an exercise price of $4.10 per ADS, subject to adjustment as set forth
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company also entered into an engagement agreement on November 7, 2016 (the &ldquo;Engagement Agreement&rdquo;), as amended on
February 16, 2017 (the &ldquo;Amendment&rdquo;), with Rodman &amp; Renshaw, a unit of H.C. Wainwright&nbsp;&amp; Co., LLC
(the &ldquo;Placement Agent&rdquo;), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent
for the Company in connection with the offering. The Company agreed to pay the Placement Agent a fee equal to 7% of the gross
proceeds from the sales of shares under the transaction. In addition, the Company shall pay the Placement Agent a cash
management fee equal to 1% of the aggregate gross proceeds raised in the transaction. The Company also agreed to reimburse
the Placement Agent $45,000 for expenses in connection with this offering. The Placement Agent will receive compensation
warrants to purchase up to a number of ADSs equal to 5% of the ADSs purchased by investors in this offering. Such warrants
shall have the same terms as the warrants issued to the investors in the offering. The Engagement Agreement, as amended, has
a term of 180 days and provides the Placement Agent with a right of first refusal <FONT STYLE="color: windowtext">to act as
the Company&rsquo;s exclusive financial advisor or lead manager, underwriter or placement agent during the 10-month period
following consummation of an offering if the Company or any subsidiaries decides to enter into any merger, acquisition or
disposition transaction using a financial advisor  or a debt financing using a <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manager</FONT>
or to raise funds by means of a public offering or a private placement of equity or debt securities using an underwriter
or placement agent, other than to current investors or certain investors previously identified to the Placement Agent. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ADSs to be issued
in the registered direct offering will be issued pursuant to a prospectus supplement which will be filed with the Securities and
Exchange Commission (the &ldquo;SEC&rdquo;), in connection with a takedown from the Company&rsquo;s shelf registration statement
on Form F-3 (File No. 333-194338) (the &ldquo;Registration Statement&rdquo;), which became effective on April 4, 2014, and the
base prospectus contained in such Registration Statement. This report shall not constitute an offer to sell or the solicitation
to buy nor shall there be any sale of the ADSs or warrants in any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants and the
ADSs underlying the warrants are being offered and sold pursuant to an exemption from the registration requirements under Section
4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Rule 506 of Regulation D promulgated thereunder.
The investors have represented that they are accredited investors, as that term is defined in Regulation&nbsp;D, or qualified institutional
buyers as defined in Rule 144(A)(a), and have acquired the warrants and the ADSs underlying the warrants as principals for their
own account and have no arrangements or understandings for any distribution thereof. The offer and sale of the foregoing securities
is being made without any form of general solicitation or advertising. The warrants and the ADSs underlying the warrants have not
been registered under the Securities Act of 1933 or applicable state securities laws. Accordingly, the warrants and underlying
ADSs may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption
from the registration requirements of the Securities Act and such applicable state securities laws.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summaries
of the terms of the Engagement Agreement, Amendment, Purchase Agreement and Warrants are subject to, and qualified in their entirety,
by such documents attached hereto as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, and are incorporated herein by reference.
The opinion of Doron Tikotzky Kantor Gutman Cederboum &amp; SRFK relating to the legality of the issuance and sale of the ordinary
shares underlying the ADSs is attached as Exhibit 5.1.&nbsp; The Company previously announced the offering in a press release issued
on February 17, 2017, which was included as an exhibit to a Report on Form 6-K filed with the SEC on February 17, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warning Concerning Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report of Foreign
Private Issuer on Form 6-K contains statements which constitute forward looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company&rsquo;s present
intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons,
including some reasons which are beyond the Company&rsquo;s control. For example, this report states that the offering is expected
to close on or about February 23, 2017. In fact, the closing of the offering is subject to various conditions and contingencies
as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified
contingencies do not occur, this Offering may not close. For this reason, among others, you should not place undue reliance upon
the Company&rsquo;s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update
any forward looking statements in order to reflect any event or circumstance that may arise after the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 88%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Opinion of Doron Tikotzky Kantor Gutman Cederboum &amp; SRFK</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Letter Agreement between Rodman &amp; Renshaw, a unit of H.C.
    Wainwright &amp; Co., LLC, and XTL Biopharmaceuticals Ltd. dated November 7, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amendment to Letter Agreement between Rodman &amp; Renshaw, a
    unit of H.C. Wainwright &amp; Co., LLC, and XTL Biopharmaceuticals Ltd. dated February 16, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Securities Purchase Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Warrant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consent of Doron Tikotzky Kantor Gutman Cederboum &amp; SRFK (contained in Exhibit 5.1)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-left: 27pt"><FONT STYLE="font-size: 10pt"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 27pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date: February 21, 2017</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 27pt"><FONT STYLE="font-size: 10pt">/s/ Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in"><FONT STYLE="font-size: 10pt">Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>v460062_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><B><IMG SRC="logo.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">February 21, 2017</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">XTL Biopharmaceuticals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">5 HaCharoshet St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Raanana 4365603</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dear Sir and Madam:</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">Re:</TD><TD STYLE="text-align: justify"><B><U>XTL Biopharmaceuticals
                                         Ltd. &mdash; 100,000,000 Ordinary Shares</U></B></TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><B><U>represented by 1,000,000 American
                                         Depositary Shares</U></B></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dear Sir and Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as Israeli
counsel to XTL Biopharmaceuticals Ltd. (the &ldquo;Company&rdquo;), a company organized under the laws of the State of Israel in
connection with the issuance and sale of an aggregate of 100,000,000 ordinary shares, NIS 0.1 par value per share, (the &ldquo;Ordinary
Shares&rdquo;) represented by 1,000,000 American Depositary Shares (the &ldquo;ADSs&rdquo;) being offered by the Company, pursuant
to the terms of securities purchase agreements dated February 17, 2017 between the Company and the investors party thereto.&nbsp;&nbsp;The
ADSs are being issued pursuant to a registration statement on Form F-3 (Registration Statement No. 333-194338) (the &ldquo;Registration
Statement&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act of
1933, as amended (the &ldquo;Securities Act&rdquo;), the prospectus dated April 4, 2014, and the prospectus supplement dated February
21, 2017, filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As counsel to the Company
in Israel, we have examined copies of the Articles of Association, as amended, of the Company and such corporate records, instruments,
and other documents relating to the Company and such matters of law as we have considered necessary or appropriate for the purpose
of rendering this opinion. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents
submitted to us as originals, and the conformity to authentic originals of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing,
we advise you that in our opinion, the Ordinary Shares underlying the ADSs are duly authorized, legally issued, fully-paid and
non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are members of the
Israeli bar, and the opinions expressed herein are limited to questions arising under the laws of the State of Israel, and we disclaim
any opinion whatsoever with respect to matters governed by the laws of any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to
the use of this opinion as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 6-K to be filed with the Commission on February
21, 2017, which will be incorporated by reference in the Registration Statement, and to the reference to us under the caption &ldquo;Legal
Matters&rdquo; in the prospectus included in the Registration Statement.&nbsp;&nbsp;<FONT STYLE="background-color: white">In giving
such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the
Securities Act or the rules and regulations of the Commission.</FONT></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron Tikotzky Kantor Gutman Cederboum &amp; Co.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>v460062_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="pg1img1_ex10-1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0.5in; margin-bottom: 0pt; text-align: right">November 7, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>STRICTLY CONFIDENTIAL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL Biopharmaceuticals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5 Hacharoshet Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raanana, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Joshua Levine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Levine:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter agreement
(this &ldquo;<U>Agreement</U>&rdquo;) constitutes the agreement between XTL Biopharmaceuticals Ltd. (the &ldquo;<U>Company</U>&rdquo;)
and Rodman &amp; Renshaw, a unit of H.C. Wainwright &amp; Co., LLC (&ldquo;<U>Rodman</U>&rdquo;) that Rodman shall serve as the
exclusive agent, advisor or underwriter in any offering (each, an &ldquo;<U>Offering</U>&rdquo;) of securities of the Company
(&ldquo;<U>Securities</U>&rdquo;) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities
issued in connection therewith shall be mutually agreed upon by the Company and Rodman and nothing herein implies that Rodman
would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to
issue any Securities. It is understood that Rodman&rsquo;s assistance in an Offering will be subject to the satisfactory completion
of such investigation and inquiry into the affairs of the Company as Rodman deems appropriate under the circumstances and to the
receipt of all internal approvals of Rodman in connection with the transaction. The Company expressly acknowledges and agrees
that Rodman&rsquo;s involvement in an Offering is strictly on a reasonable best efforts basis, unless otherwise agreed, and that
the consummation of an Offering will be subject to, among other things, market conditions. The execution of this Agreement does
not constitute a commitment by Rodman to purchase the Securities and does not ensure a successful Offering of the Securities or
the success of Rodman with respect to securing any other financing on behalf of the Company. Rodman may retain other brokers,
dealers, agents or underwriters on its behalf in connection with an Offering, and any payments to such shall be from Rodman&rsquo;s
share of the economics hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation;
Reimbursement</U>. At the closing of each Offering (each, a &ldquo;<U>Closing</U>&rdquo;), the Company shall compensate Rodman
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Cash
Fee</I>. The Company shall pay to Rodman a cash fee, or as to an underwritten Offering an underwriter discount, equal to 7% of
the aggregate gross proceeds raised in each Offering, except that in relation to any proceeds raised from any of the existing
shareholders of the Company participating in an Offering and listed in <B><U>Schedule A</U></B> attached hereto (the &ldquo;<U>Existing
Shareholders</U>&rdquo;), the Company shall pay to Rodman a cash fee, or as to an underwritten Offering an underwriter discount,
equal to 3.5% of the aggregate gross proceeds raised from such Existing Shareholders in each such Offering. In addition, the Company
shall pay Rodman a cash management fee equal to 1% of the aggregate gross proceeds raised in each Offering. <STRIKE> </STRIKE></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">430 Park Avenue | New York, New York 10022
| 212.356.0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Security services provided by H.C. Wainwright
&amp; Co., LLC | Member: FINRA/SIPC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Warrant
Coverage</I>. The Company shall issue to Rodman or its designees at each Closing, warrants (the &ldquo;<U>Rodman Warrants</U>&rdquo;)
to purchase that number of American Depositary Shares of the Company (&ldquo;<U>ADSs</U>&rdquo;) equal to 5% of the aggregate
number of ADSs placed in each Offering. The Rodman Warrants shall have the same terms as the warrants, if any, issued to investors
in the applicable Offering. If no warrants are issued to investors in an Offering, the Rodman Warrants shall be in a customary
form reasonably acceptable to Rodman, have a term of 5 years and an exercise price equal to 120% of the then market price of the
ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Expense
Allowance</I>. Out of the proceeds of each Closing, the Company also agrees to pay Rodman an expense allowance equal to (i) $35,000
for accountable fees and expenses of HCW (other than legal) and (ii) the greater of $75,000 and 1% of the gross proceeds raised
in such Offering for legal counsel fees and expenses (provided, however, that such reimbursement amount in no way limits or impairs
the indemnification and contribution provisions of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Right
of First Refusal</I>. If within the 10-month period following consummation of each Offering, the Company or any of its subsidiaries
(a) decides to dispose of or acquire business units or acquire any of its outstanding securities or make any exchange or tender
offer or enter into a merger, consolidation or other business combination or any recapitalization, reorganization, restructuring
or other similar transaction, including, without limitation, an extraordinary dividend or distributions or a spin-off or split-off,
and the Company decides to retain a financial advisor for such transaction, Rodman (or any affiliate designated by Rodman) shall
have the right to act as the Company&rsquo;s exclusive financial advisor for any such transaction; or (b) decides to finance or
refinance any indebtedness using a manager or agent, Rodman (or any affiliate designated by Rodman) shall have the right to act
as lead manager, lead placement agent or lead agent with respect to such financing or refinancing; or (iii) decides to raise funds
by means of a public offering or a private placement of equity or debt securities using an underwriter or placement agent (other
than a private placement, with no placement agent or investment banker, of equity or debt securities </FONT>with<FONT STYLE="font-family: Times New Roman, Times, Serif">
existing shareholders of the Company or the investors set forth on <B><U>Schedule B</U></B>), Rodman (or any affiliate designated
by Rodman) shall have the right to act as lead underwriter or lead placement agent for such financing. If Rodman or one of its
affiliates decides to accept any such engagement, the agreement governing such engagement will contain, among other things, provisions
for customary fees for transactions of similar size and nature and the provisions of this Agreement, including indemnification,
which are appropriate to such a transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term
and Termination of Engagement; Exclusivity</U>. The term of Rodman&rsquo;s exclusive engagement will begin on the date hereof
and end 90 days following the date hereof (the &ldquo;<U>Term</U>&rdquo;). Notwithstanding anything to the contrary contained
herein, the Company agrees that the provisions relating to the payment of fees, reimbursement of expenses, indemnification and
contribution, confidentiality, conflicts, independent contractor and waiver of the right to trial by jury will survive any termination
of this Agreement. During Rodman&rsquo;s engagement hereunder, except as specifically set forth in this Agreement: (i) the Company
will not, and will not permit its representatives to, other than in coordination with Rodman, contact or solicit institutions,
corporations or other entities or individuals as potential purchasers of the Securities, (ii) the Company will not pursue any
financing transaction which would be in lieu of an Offering (other than a private placement, with no placement agent or investment
banker, of equity or debt securities with existing shareholders of the Company or the investors set forth on <B>Schedule B</B>),
and (iii) all inquiries, whether direct or indirect, from prospective investors will be referred to Rodman and will be deemed
to have been contacted by Rodman in connection with an Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information;
Reliance.</U> The Company shall furnish, or cause to be furnished, to Rodman all information requested by Rodman for the purpose
of rendering services hereunder (all such information being the &ldquo;<U>Information</U>&rdquo;). In addition, the Company agrees
to make available to Rodman upon request from time to time the officers, directors, accountants, counsel and other advisors of
the Company. The Company recognizes and confirms that Rodman (a) will use and rely on the Information, including any documents
provided to investors in each Offering (the &ldquo;<U>Offering Documents</U>&rdquo; which shall include any Purchase Agreements
(as defined below)), and on information available from generally recognized public sources in performing the services contemplated
by this Agreement without having independently verified the same; (b) does not assume responsibility for the accuracy or completeness
of the Offering Documents or the Information and such other information; and (c) will not make an appraisal of any of the assets
or liabilities of the Company. Upon reasonable request, the Company will meet with Rodman or its representatives to discuss all
information relevant for disclosure in the Offering Documents and will cooperate in any investigation undertaken by Rodman thereof,
including any document included or incorporated by reference therein. At each Offering, at the request of Rodman, the Company
shall deliver such legal letters, comfort letters and officer&rsquo;s certificates, all in form and substance satisfactory to
Rodman and its counsel as is customary for such Offering. Rodman shall be a third party beneficiary of any representations, warranties,
covenants and closing conditions made by the Company in any Offering Documents, including representations, warranties, covenants
and closing conditions made to any investor in an Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Related
Agreements</U>. At each Offering, the Company shall enter into the following additional agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Underwritten
Offering</I>. If an Offering is an underwritten Offering, the Company and Rodman shall enter into a customary underwriting agreement
in form and substance satisfactory to Rodman and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Best
Efforts Offering</I>. If an Offering is on a best efforts basis, the sale of Securities to the investors in the Offering will
be evidenced by a purchase agreement (&ldquo;<U>Purchase Agreement</U>&rdquo;) between the Company and such investors in a form
reasonably satisfactory to the Company and Rodman. Prior to the signing of any Purchase Agreement, officers of the Company with
responsibility for financial affairs will be available to answer inquiries from prospective investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Escrow
and Settlement</I>. In respect of each Offering, the Company and Rodman shall enter into an escrow agreement with a third party
escrow agent, which may also be Rodman&rsquo;s clearing agent, pursuant to which Rodman&rsquo;s compensation and expenses shall
be paid from the gross proceeds of the Securities sold. If the Offering is settled in whole or in part via delivery versus payment
(&ldquo;<U>DVP</U>&rdquo;), Rodman shall arrange for its clearing agent to provide the funds to facilitate such settlement. The
Company shall bear the cost of the escrow agent and shall reimburse Rodman for the actual out of pocket cost of such clearing
agent settlement and financing, if any</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>FINRA
Amendments</I>. Notwithstanding anything herein to the contrary, in the event that Rodman determines that any of the terms provided
for hereunder shall not comply with a FINRA rule, including but not limited to FINRA Rule 5110, then the Company shall agree to
amend this Agreement (or include such revisions in the final underwriting) in writing upon the request of Rodman to comply with
any such rules; provided that any such amendments shall not provide for terms that are less favorable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
In the event of the consummation or public announcement of any Offering, Rodman shall have the right to disclose its participation
in such Offering, including, without limitation, the placement at its cost of &ldquo;tombstone&rdquo; advertisements in financial
and other newspapers and journals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Company&rsquo;s engagement of Rodman as Offering agent, the Company hereby agrees to indemnify and hold harmless
Rodman and its affiliates, and the respective controlling persons, directors, officers, members, shareholders, agents and employees
of any of the foregoing (collectively the &ldquo;<U>Indemnified Persons</U>&rdquo;), from and against any and all claims, actions,
suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by any of them (including the
reasonable fees and expenses of counsel), as incurred, (collectively a &ldquo;<U>Claim</U>&rdquo;), that are (A) related to or
arise out of (i) any actions taken or omitted to be taken (including any untrue statements made or any statements omitted to be
made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the Company&rsquo;s
engagement of Rodman, or (B) otherwise relate to or arise out of Rodman&rsquo;s activities on the Company&rsquo;s behalf under
Rodman&rsquo;s engagement, and the Company shall reimburse any Indemnified Person for all expenses (including the reasonable fees
and expenses of counsel) as incurred by such Indemnified Person in connection with investigating, preparing or defending any such
claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation in which any Indemnified
Person is a party. The Company will not, however, be responsible for any Claim that is finally judicially determined to have resulted
from the gross negligence or willful misconduct of any person seeking indemnification for such Claim. The Company further agrees
that no Indemnified Person shall have any liability to the Company for or in connection with the Company&rsquo;s engagement of
Rodman except for any Claim incurred by the Company as a result of such Indemnified Person&rsquo;s gross negligence or willful
misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company further agrees that it will not, without the prior written consent of Rodman, settle, compromise or consent to the entry
of any judgment in any pending or threatened Claim in respect of which indemnification may be sought hereunder (whether or not
any Indemnified Person is an actual or potential party to such Claim), unless such settlement, compromise or consent includes
an unconditional, irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly
upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution of any Claim with respect to
which indemnification is being sought hereunder, such Indemnified Person shall notify the Company in writing of such complaint
or of such assertion or institution but failure to so notify the Company shall not relieve the Company from any obligation it
may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights
and defenses. If the Company so elects or is requested by such Indemnified Person, the Company will assume the defense of such
Claim, including the employment of counsel reasonably satisfactory to such Indemnified Person and the payment of the fees and
expenses of such counsel. In the event, however, that legal counsel to such Indemnified Person reasonably determines that having
common counsel would present such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes
an Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal
defenses available to it or other Indemnified Persons different from or in addition to those available to the Company, then such
Indemnified Person may employ its own separate counsel to represent or defend him, her or it in any such Claim and the Company
shall pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company fails
timely or diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified Party shall have the
right, but not the obligation, to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect
against the same, and shall be fully indemnified by the Company therefor, including without limitation, for the reasonable fees
and expenses of its counsel and all amounts paid as a result of such Claim or the compromise or settlement thereof. In addition,
with respect to any Claim in which the Company assumes the defense, the Indemnified Person shall have the right to participate
in such Claim and to retain his, her or its own counsel therefor at his, her or its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason
then (whether or not Rodman is the Indemnified Person), the Company and Rodman shall contribute to the Claim for which such indemnity
is held unavailable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and
Rodman on the other, in connection with Rodman&rsquo;s engagement referred to above, subject to the limitation that in no event
shall the amount of Rodman&rsquo;s contribution to such Claim exceed the amount of fees actually received by Rodman from the Company
pursuant to Rodman&rsquo;s engagement. The Company hereby agrees that the relative benefits to the Company, on the one hand, and
Rodman on the other, with respect to Rodman&rsquo;s engagement shall be deemed to be in the same proportion as (a) the total value
paid or proposed to be paid or received by the Company pursuant to the applicable Offering (whether or not consummated) for which
Rodman is engaged to render services bears to (b) the fee paid or proposed to be paid to Rodman in connection with such engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company&rsquo;s indemnity, reimbursement and contribution obligations under this Agreement (a) shall be in addition to, and shall
in no way limit or otherwise adversely affect any rights that any Indemnified Party may have at law or at equity and (b) shall
be effective whether or not the Company is at fault in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Engagement to the Company</U>. The Company acknowledges that Rodman has been retained only by the Company, that Rodman is providing
services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company&rsquo;s engagement
of Rodman is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or partner of the
Company or any other person not a party hereto as against Rodman or any of its affiliates, or any of its or their respective officers,
directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Securities Exchange
Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;)), employees or agents. Unless otherwise expressly agreed in writing
by Rodman, no one other than the Company is authorized to rely upon this Agreement or any other statements or conduct of Rodman,
and no one other than the Company is intended to be a beneficiary of this Agreement. The Company acknowledges that any recommendation
or advice, written or oral, given by Rodman to the Company in connection with Rodman&rsquo;s engagement is intended solely for
the benefit and use of the Company&rsquo;s management and directors in considering a possible Offering, and any such recommendation
or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used or relied upon for
any other purpose. Rodman shall not have the authority to make any commitment binding on the Company. The Company, in its sole
discretion, shall have the right to reject any investor introduced to it by Rodman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">H.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Rodman&rsquo;s Liability to the Company</U>. Rodman and the Company further agree that neither Rodman nor any of its affiliates
or any of its their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security holders or creditors,
or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for
an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief arising out
of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses
that arise out of or are based on any action of or failure to act by Rodman and that are finally judicially determined to have
resulted solely from the gross negligence or willful misconduct of Rodman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to
agreements made and to be fully performed therein. Any disputes that arise under this Agreement, even after the termination of
this Agreement, will be heard only in the state or federal courts located in the City of New York, State of New York. The parties
hereto expressly agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New
York. The parties hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court
sitting in the City and State of New York. In the event of the bringing of any action, or suit by a party hereto against the other
party hereto, arising out of or relating to this Agreement, the party in whose favor the final judgment or award shall be entered
shall be entitled to have and recover from the other party the costs and expenses incurred in connection therewith, including
its reasonable attorneys&rsquo; fees. Any rights to trial by jury with respect to any such action, proceeding or suit are hereby
waived by Rodman and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">J.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery or fax, if sent to Rodman,
to H. C. Wainwright &amp; Co., LLC, at the address set forth on the first page hereof, e-mail: notices@rodm.com, Attention: Head
of Investment Banking, and if sent to the Company, to the address set forth on the first page hereof, Attention: Chief Executive
Officer. Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery or overnight
delivery shall be deemed received on the date of the relevant written record of receipt, and notices delivered by fax shall be
deemed received as of the date and time printed thereon by the fax machine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">K.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conflicts</U>.
The Company acknowledges that Rodman and its affiliates may have and may continue to have investment banking and other relationships
with parties other than the Company pursuant to which Rodman may acquire information of interest to the Company. Rodman shall
have no obligation to disclose such information to the Company or to use such information in connection with any contemplated
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">L.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Anti-Money
Laundering</U>. To help the United States government fight the funding of terrorism and money laundering, the federal laws of
the United States requires all financial institutions to obtain, verify and record information that identifies each person with
whom they do business. This means we must ask you for certain identifying information, including a government-issued identification
number (e.g., a U.S. taxpayer identification number) and such other information or documents that we consider appropriate to verify
your identity, such as certified articles of incorporation, a government-issued business license, a partnership agreement or a
trust instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">M.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.
The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and provisions
of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement,
document or instrument to which it is a party or bound. This Agreement shall not be modified or amended except in writing signed
by Rodman and the Company. This Agreement shall be binding upon and inure to the benefit of both Rodman and the Company and their
respective assigns, successors, and legal representatives. This Agreement constitutes the entire agreement of Rodman and the Company
with respect to this Offering and supersedes any prior agreements with respect to the subject matter hereof. If any provision
of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision
in any other respect, and the remainder of the Agreement shall remain in full force and effect. This Agreement may be executed
in counterparts (including facsimile counterparts), each of which shall be deemed an original but all of which together shall
constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In acknowledgment
that the foregoing correctly sets forth the understanding reached by Rodman and the Company, please sign in the space provided
below, whereupon this letter shall constitute a binding Agreement as of the date indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RODMAN &amp; RENSHAW, A UNIT OF H.C.
WAINWRIGHT &amp; CO., LLC</B></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></td>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Mark Viklund</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Mark Viklund</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: CEO</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>XTL
    BIOPHARMACEUTICALS LTD.</B></FONT></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></td>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Josh Levine</FONT></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: Josh Levine</FONT></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: CEO</FONT></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alex Rabinovitch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Bassa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors represented by Benjamin Guzman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yellin Lapidot</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IBI Investment House</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Altshuler Shaham</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yeda Research &amp; Development Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Noked Opportunity Fund</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tomer Zimmerman/Osnat Yaffe</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avi Gantz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zamir Bar Zion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pontifax funds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>v460062_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="pg1img1_ex10-2.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">February 16, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>STRICTLY CONFIDENTIAL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL Biopharmaceuticals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5 Hacharoshet Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raanana, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Joshua Levine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Levine:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reference is made to
the engagement agreement (the &ldquo;<U>Engagement Agreement</U>&rdquo;), dated November 7, 2016, by and between XTL Biopharmaceuticals
Ltd. (the &ldquo;<U>Company</U>&rdquo;) and Rodman &amp; Renshaw, a unit of H.C. Wainwright &amp; Co., LLC (&ldquo;<U>Rodman</U>&rdquo;)
pursuant to which Rodman shall serve as the exclusive agent, advisor or underwriter of the Company in any Offering. Defined terms
used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and Rodman hereby agree to amend and restate the first sentence of Section B of the Engagement Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&ldquo;The term
of Rodman&rsquo;s exclusive engagement will begin on the date hereof and end 180 days following the date hereof (the &ldquo;<U>Term</U>&rdquo;).&rdquo;
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as expressly
set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the
execution of this agreement and shall not be in any way changed, modified or superseded by the terms set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement may
be executed in two or more counterparts and by facsimile or &ldquo;.pdf&rdquo; signature or otherwise, and each of such counterparts
shall be deemed an original and all of such counterparts together shall constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[<I>Remainder of page
intentionally left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">430 Park Avenue | New York, New York 10022
| 212.356.0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Security services provided by H.C. Wainwright
&amp; Co., LLC | Member: FINRA/SIPC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">IN WITNESS WHEREOF, this agreement
is executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">Very truly yours,</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RODMAN &amp; RENSHAW, A UNIT
OF H.C. WAINWRIGHT &amp; CO., LLC</B></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <td colspan="2" style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 5%">By:</td>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s/ Edward Silvera</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Name: Edward Silvera</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Title: COO</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>XTL BIOPHARMACEUTICALS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">By:</td>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify">/s/ Josh Levine</td>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">Name: Josh Levine</td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">Title: CEO</td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to XTLB Engagement Agreement
Amendment</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>v460062_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-transform: uppercase; text-align: right; text-indent: -0.5in"><FONT STYLE="text-transform: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-transform: uppercase; text-align: right; text-indent: -0.5in"><FONT STYLE="text-transform: none"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of February 16, 2017, between XTL Biopharmaceuticals Ltd., a company
organized under the laws of Israel (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto
(each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the
terms and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities Act
of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) as to the Shares and (ii) an exemption from the registration requirements
of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder as to the Warrants, the
Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the
Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of
which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:</P>

<P STYLE="color: red; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>ADS(s)</U>&rdquo;
means American Depositary Shares issued pursuant to the Deposit Agreement (as defined below), each representing one-hundred (100)
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States, a
legal holiday in the State of Israel or any day on which banking institutions in the State of New York or in the State of Israel
are authorized or required by law or other governmental action to close; <U>provided</U>, <U>however</U>, that, for calculating
Business Days with respect to any action to be taken by the Company hereunder, Friday after 1:00 p.m. (Tel Aviv time) shall not
be considered a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)
the Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than
the third Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Israel Counsel</U>&rdquo; means Kantor &amp; Co., with offices located at 12 Abba Hillel Silver Rd., Ramat Gan, Israel 52506.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
US Counsel</U>&rdquo; means Sichenzia Ross Ference Kesner LLP, with offices located at 61 Broadway, New York, New York 10006.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Deposit
Agreement</U>&rdquo; means the Deposit Agreement dated August 31, 2005, among the Company, The Bank of New York Mellon as Depositary
and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Depositary</U>&rdquo;
means The Bank of New York Mellon, as Depositary under the Deposit Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>IFRS</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share(s)</U>&rdquo; means the ordinary shares of the Company, par value NIS 0.10 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Ordinary Shares or ADSs, including, without limitation, any debt, preferred stock, right, option, warrant or
other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
to receive, Ordinary Shares or ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per
ADS Purchase Price</U>&rdquo; equals $2.50, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of ADSs and/or Ordinary Shares that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Rodman &amp; Renshaw, a unit of H.C. Wainwright &amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with
the Commission and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement on Form F-3 with Commission (File No. 333-194338) which registers
the sale of the Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the ADSs, Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the Ordinary Shares, as represented by ADSs issued pursuant to the Deposit Agreement, each ADS representing one-hundred (100)
Ordinary Shares, issued and issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing ADSs and/or Ordinary Shares).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for ADSs, each ADS representing one-hundred (100)
Ordinary Shares and Warrants purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement
and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Nasdaq Capital Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the ADSs and/or the Ordinary Shares are listed or quoted
for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, the New York Stock Exchange or the Tel Aviv Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants and any other documents or agreements executed in connection with the transactions
contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or
quoted on a Trading Market, the daily volume weighted average price of an ADS for such date (or the nearest preceding date) on
the Trading Market on which an ADS is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB is not a Trading Market, the volume weighted average
price of an ADS for such date (or the nearest preceding date) on the OTCQB, (c) if ADSs are not then listed or quoted for trading
on the OTCQB and if prices for ADSs are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of an ADS
so reported, or (d) in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good
faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
ADSs</U>&rdquo; means ADSs representing the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the ADS purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof,
which Warrants shall be exercisable on the six month anniversary of the date of issuance and have a term of exercise equal to five
years following the date of initial exercisability, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the Ordinary Shares issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $2,500,000 of ADSs and Warrants exercisable for ADSs as calculated pursuant Section 2.2(a).
The Company shall deposit the Shares and instruct the Depositary to deliver to each Purchaser its respective ADSs and a Warrant
as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section
2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing
shall occur at the offices of EGS or such other location as the parties shall mutually agree. Unless otherwise directed by the
Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)<I> </I>(i.e.,
on the Closing Date, the Company shall issue the ADSs registered in the Purchasers&rsquo; names and addresses and released by the
Depositary directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such ADSs, the Placement
Agent shall promptly electronically deliver such ADSs to the applicable Purchaser, and payment therefor shall be made by the Placement
Agent (or its clearing firm) by wire transfer to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;legal
opinions of Company US Counsel and Company Israel Counsel, substantially in the forms of <U>Exhibit B-1</U> and <U>Exhibit B-2</U>
attached hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Depositary instructing the Depositary to deliver
contemporaneously with the Closing via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
a number of ADSs equal to such Purchaser&rsquo;s Subscription Amount divided by the Per ADS Purchase Price, per the instructions
of such Purchaser or the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Warrant to purchase up to a number of ADSs equal to 100% of such Purchaser&rsquo;s ADSs per the instructions of such Purchaser
or the Placement Agent, with an exercise price equal to $4.10, subject to adjustment therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Conditions</U>.<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date hereof to the Closing Date, trading in the ADSs or Ordinary Shares shall not have been suspended by the Commission or
any Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by
such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York
State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international
calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the
reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed
a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the
issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and, if applicable under the laws of the jurisdiction in which they are formed, in good standing under the laws of the
jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets
and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any
of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.
Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation
or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be
expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)
a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the
Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith
or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the
terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)
and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement,
(iii) application(s) to each applicable Trading Market for the listing of the ADSs and Warrant ADSs for trading thereon in the
time and manner required thereby and (iv) such filings as are required to be made under applicable state securities laws and the
Israeli Securities Authority and the Tel Aviv Stock Exchange, (v) filings required by the Israeli Registrar of Companies, and (vi)
notice of this Transaction to the Office of the Chief Scientist of the Ministry of Industry Trade and Labor of the State of Israel,
should Israeli Company Counsel determine such notice is required (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum
number of Ordinary Shares issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration
Statement in conformity with the requirements of the Securities Act, which became effective on&nbsp;April 4, 2014 (the &ldquo;<U>Effective
Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of
this Agreement. The Company and the Depositary have prepared and filed with the Commission a registration statement relating to
ADSs on Form F-6 (File No. 333-194338) for registration under the Securities Act (the &ldquo;<U>ADS Registration Statement</U>&rdquo;).
The Registration Statement and ADS Registration Statement are effective under the Securities Act and no stop order preventing or
suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued
by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened
by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the
Commission pursuant to Rule 424(b). At the time that the Registration Statement, the ADS Registration Statement and any amendments
thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments
thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus
or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects
to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form F-3. The Company is eligible
to use Form F-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value of
securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth in General
Instruction I.B.6 of Form F-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The equity capitalization of the Company is as set forth on <U>Schedule 3.1(g)</U>. The Company has not issued any capital stock
since May 5, 2016. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to
participate in the transactions contemplated by the Transaction Documents. Except as set forth on <U>Schedule 3.1(g)</U> and as
a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to,
calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any Person any right to subscribe for or acquire, any ADSs, Ordinary Shares or Ordinary Share Equivalents
or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to issue additional ADSs, Ordinary Shares or Ordinary Share Equivalents or capital stock of any Subsidiary.
The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue ADSs, Ordinary Shares or Ordinary
Share Equivalents or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of
Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no
contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem
a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo;
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws where applicable,
and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase
securities. Except for the Required Approvals, no further approval or authorization of any stockholder, the Board of Directors
or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other
similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on
a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject
to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect
at the time of filing. Such financial statements have been prepared in accordance with IFRS accounting principles applied on a
consistent basis during the periods involved (&ldquo;<U>IFRS</U>&rdquo;), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by IFRS,
and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for
the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has
been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
Company&rsquo;s financial statements pursuant to IFRS or disclosed in filings made with the Commission, (iii) the Company has not
altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property
to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)
the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock
option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except
for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability,
fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to
the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, which could result
in a Material Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any
investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or
any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens
for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with IFRS
and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by
the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the
Subsidiaries are in compliance in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
and which the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)
years from the date of this Agreement, except as would not reasonably be expected to have a Material Adverse Effect. Neither the
Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports,
a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights
of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the
Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of
the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the
Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party
to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof and applicable to the Company and the Subsidiaries,
and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof
and as of the Closing Date and applicable to the Company and the Subsidiaries. The Company and the Subsidiaries maintain a system
of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with
management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with IFRS and to maintain asset accountability, (iii) access to assets is permitted only in accordance
with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries
have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by
the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the
time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently
filed Form 20-F under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most
recently filed Form 20-F under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes
in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries
that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the
Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank
or other Person with respect to the transactions contemplated by the Transaction Documents. Other than for Persons directly engaged
by a Purchaser, if any, the Purchasers shall have no obligation with respect to any fees or with respect to any claims made by
or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions
contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will
not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject
to registration under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act
of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements</U>. The Ordinary Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Ordinary Shares under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the ADSs or Ordinary Shares are or have been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will
not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The ADSs are currently
eligible for electronic transfer through The Depository Trust Company or another established clearing corporation and the Company
is current in payment of the fees to The Depository Trust Company (or such other established clearing corporation) in connection
with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its jurisdiction of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the
Disclosure Schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement
of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances
under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the
date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require
the registration of the Warrants or Warrant Shares under the Securities Act, or (ii) of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U>
sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which
the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)
any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether
or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance
with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or
of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any
provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
The Company&rsquo;s accounting firm is as set forth in the Prospectus. To the knowledge and belief of the Company, such accounting
firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect
to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ended December 31, 2016.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the
transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby
and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents
and the transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company
further represents to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="text-underline-style: double"><U>Acknowledgement
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers
has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short,
securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities
for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without
limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement
transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and
counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently
may have a &ldquo;short&rdquo; position in the ADSs and/or Ordinary Shares, and (iv) each Purchaser shall not be deemed to have
any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.</FONT><FONT STYLE="text-underline-style: double"><U>
</U></FONT>The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at
various times during the period that the Securities are outstanding, including, without limitation, during the periods that the
value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any)
could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities
are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute a breach of
any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any
other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement
agent in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint,
or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received
any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket
clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing
of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall,
suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any
Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent
decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have
a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA.&nbsp; The Company has not been informed by the
FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed,
produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product
being developed or proposed to be developed by the Company.<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Warrants or the Warrant Shares by the Company to the Purchasers
as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Warrant
or Warrant Shares by any form of general solicitation or general advertising. The Company has offered the Warrants and Warrant
Shares for sale only to the Purchasers and certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Disqualification Events</U>. With respect to the Warrant and Warrant Shares to be offered and sold hereunder in reliance on Rule
506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered
Person&rdquo;</U>) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under
the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2) or
(d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished
to the Purchasers a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale
of any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to
become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they
shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise
in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary
course of its business. Such Purchaser understands that the Warrants and the Warrant Shares are &ldquo;restricted securities&rdquo;
and have not been registered under the Securities Act or any applicable state securities law and is acquiring such Securities as
principal for his, her or its own account and not with a view to or for distributing or reselling such Securities or any part thereof
in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such
Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities
Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&rsquo;s right to sell
such Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
which it exercise any Warrants, it will be, either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A(a)
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and, has been afforded, (i) the opportunity to ask such questions as it
has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the
offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company
and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate
its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without
unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp;
Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp;
Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities
and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser
agrees need not be provided to it.&nbsp; In connection with the issuance of the Securities to such Purchaser, neither the Placement
Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof.
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s
representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents
and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction)<FONT STYLE="color: windowtext">. Notwithstanding the foregoing, for the
avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any actions
with respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities
of the Company in order for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented
at any seminar or any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">The Company acknowledges
and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right
to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt,
nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal
of Legends.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrants and Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any
transfer of Warrants or Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or
to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor
thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the
form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not
require registration of such transferred Warrant under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Warrants or Warrant
Shares in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS EXERCISABLE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION
THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer
or grant a security interest in some or all of the Warrants or Warrant Shares to a financial institution that is an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser
may transfer pledged or secured Warrants or Warrant Shares to the pledgees or secured parties. Such a pledge or transfer would
not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall
be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s
expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Warrants and Warrant
Shares may reasonably request in connection with a pledge or transfer of the Warrants or Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates
evidencing the Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while
a registration statement covering the resale of such security is effective under the Securities Act, or (ii) following any sale
of such Warrant Shares pursuant to Rule 144, or (iii) if such Warrant Shares are eligible for sale under Rule 144, or (iv) if such
legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly
if required by the Transfer Agent to effect the removal of the legend hereunder. If all or any portion of a Warrant is exercised
at a time when there is an effective registration statement to cover the resale of the Warrant Shares, or if such Warrant Shares
may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free
of all legends. The Company agrees that following such time as such legend is no longer required under this Section 4.1(c), the
Company will, no later than the earlier of (i) three Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing
Warrant Shares, as applicable, issued with a restrictive legend (such third Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;),
deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and
other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the
restrictions on transfer set forth in this Section 4. Certificates for Warrant Shares subject to legend removal hereunder shall
be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository
Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard
settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs
as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares (based on the VWAP of an ADS on the date such Securities are submitted
to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing
to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal
Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be
delivered) to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such
Purchaser that is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases
(in an open market transaction or otherwise) ADSs to deliver in satisfaction of a sale by such Purchaser of all or any portion
of the number of ADSs, or a sale of a number of ADSs equal to all or any portion of the number of ADSs, that such Purchaser anticipated
receiving from the Company without any restrictive legend, then an amount equal to the excess of such Purchaser&rsquo;s total purchase
price (including brokerage commissions and other out-of-pocket expenses, if any) for the ASDs so purchased (including brokerage
commissions and other out-of-pocket expenses, if any) (the &ldquo;<FONT STYLE="font-weight: normal"><U>Buy-In Price</U></FONT>&rdquo;)
over the product of (A) such number of Warrant Shares that the Company was required to deliver to such Purchaser by the Legend
Removal Date multiplied by (B) the lowest closing sale price of an ADS on any Trading Day during the period commencing on the date
of the delivery by such Purchaser to the Company of the applicable Warrant Shares (as the case may be) and ending on the date of
such delivery and payment under this Section 4.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ADSs shall be issued free of legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to maintain
the registration of the Ordinary Shares under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions
in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date
hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of
the Warrant Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in compliance with Rule
144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to
satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i)
or becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public
Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to
a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability
to sell the Warrant Shares, an amount in cash equal to two percent (2.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s
Warrants on the day of a Public Information Failure and on every thirtieth (30<SUP>th</SUP>) day (pro rated for periods totaling
less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time
that such public information is no longer required&nbsp; for the Purchasers to transfer the Warrant Shares pursuant to Rule 144.&nbsp;
The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b) are referred to herein as &ldquo;<U>Public
Information Failure Payments</U>.&rdquo;&nbsp; Public Information Failure<B> </B>Payments shall be paid on the earlier of (i) the
last day of the calendar month during which such Public Information Failure<B> </B>Payments are incurred and (ii) the third (3<SUP>rd</SUP>)
Business Day after the event or failure giving rise to the Public Information Failure<B> </B>Payments is cured.&nbsp; In the event
the Company fails to make Public Information Failure<B> </B>Payments in a timely manner, such Public Information Failure<B> </B>Payments
shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit
such Purchaser&rsquo;s right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right
to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Warrants or Warrant Shares or that would be integrated with the offer
or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder
approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by 9:00 a.m. (New York City time) on the date hereof, issue a press release
disclosing the material terms of the transactions contemplated hereby, and (b) file a Report on Form 6-K, including the Transaction
Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of
such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information
delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees
or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance
of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company
and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated
hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement
without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each
Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except
if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice
of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any
Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without
the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of
final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations,
in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities
under the Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent
that the Company delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company
hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public
information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission on a Report on Form 6-K. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. Except as set forth in the Registration Statement, the Company shall use the net proceeds from the sale of the
Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the
Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b) for the redemption of any ADSs, Ordinary Shares or Ordinary Share Equivalents, (c) for the settlement of any outstanding litigation
or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not
an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is based upon a breach of such Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction
Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such
Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence,
willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may
be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall
have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any
Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time
to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not
be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s
prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a
loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties,
covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or
defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any
cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject
to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Ordinary Shares</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of Ordinary Shares for the purpose of enabling the Company to issue
ADSs and Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of ADSs and Warrants</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the ADSs, Ordinary
Shares and Warrants on each Trading Market on which each is currently listed and, concurrently with the Closing, the Company shall
apply to list or quote all of the ADSs, Warrants and Warrant Shares on such Trading Market and promptly secure the listing of all
of the ADSs, Warrants and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the
ADSs, Ordinary Shares and Warrants traded on any other Trading Market, it will then include in such application all of the Shares
and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed
or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue
the listing and trading of its ADSs, Ordinary Shares and Warrants on a Trading Market and will comply in all respects with the
Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to
maintain the eligibility of the ADSs, Ordinary Shares and Warrants for electronic transfer through the Depository Trust Company
or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company
or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>. From the date hereof until the two year anniversary of the date hereof, the Company shall be prohibited from
effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of ADSs or Ordinary Share
Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo;
means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable
or exercisable for, or include the right to receive additional ADSs either (A) at a conversion price, exercise price or exchange
rate or other price that is based upon and/or varies with the trading prices of or quotations for the ADSs at any time after the
initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the ADSs or (ii) enters into, or effects
a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities
at a future determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such
issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to
treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4.<FONT STYLE="color: windowtext">&nbsp; </FONT>Each Purchaser, severally and not jointly with the other
Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company
pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence
and terms of this transaction and the information included in the Disclosure Schedules.&nbsp; N<FONT STYLE="color: windowtext">otwithstanding
the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and
agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions
in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting
any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in
Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company
to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4.&nbsp; </FONT>Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only
apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the
Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext"><U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the
Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required
in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance
with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext"><U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Warrant and Warrant Shares as required
under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as
the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Warrant and Warrant
Shares for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the
United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext"><U>Registration
Statement</U>. As soon as </FONT>practicable (and in any event within 45 calendar days of the date of this Agreement), the Company
shall file a registration statement on Form F-3 (or other appropriate form if the Company is not then F-3 eligible) providing for
the resale by the Purchasers of the Warrant Shares issued and issuable upon exercise of the Warrants.&nbsp; The Company shall use
commercially reasonable efforts to cause such registration to become effective within 181 days following the Closing Date and to
keep such registration statement effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before February 27, 2017; <U>provided</U>, <U>however</U>, that no such termination will affect
the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Depositary fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and
any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of
any Securities to the Purchasers and shall reimburse the Purchasers for any fees charged to Purchasers by the Depositary in connection
with holding the ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the ADSs (based on initial
Subscription Amounts hereunder) or, in the case of a waiver, by the party against whom enforcement of any such waived provision
is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group
of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver
of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver
in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed
amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative
to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser, Any amendment effected in accordance with accordance with this Section 5.5 shall be binding upon each Purchaser and
holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action
or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action
or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities for the applicable
statute of limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the
case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any ADSs or Ordinary Shares
subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid
to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the
Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It
is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the
Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken
or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to ADS and share prices and ADSs and Ordinary Shares in any Transaction Document shall be subject to adjustment
for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the ADSs and Ordinary
Shares that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>xtl biopharmaceuticals ltd.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; text-decoration: underline; layout-grid-mode: line"><U>Address for Notice:</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="width: 45%; layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-left: 9pt; layout-grid-mode: line">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; layout-grid-mode: line">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; layout-grid-mode: line">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">Name:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; layout-grid-mode: line">E-Mail:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line">Title:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; layout-grid-mode: line">Fax:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="layout-grid-mode: line">With a copy to (which shall not constitute notice):</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; layout-grid-mode: line">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">XTLB</FONT>
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Facsimile Number of Authorized Signatory: __________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address for Notice to Purchaser (and delivery of Warrants):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address for Delivery of Share to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">DTC Participant name and number: ________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Contact of DTC Participant: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Telephone Number of Participant Contact: _____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ADSs: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Warrant ADSs: __________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;Notwithstanding
anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase
the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company
to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the
Closing shall occur on the third (3<SUP>rd</SUP>) Trading Day following the date of this Agreement and (iii) any condition to Closing
contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the
above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition
and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement,
instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>v460062_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY NOR
THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED
BY AMERICAN DEPOSITARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>XTL BIOPHARMACEUTICALS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Warrant No.:__________</TD>
    <TD STYLE="width: 50%; font-size: 10pt">Issue Date: February ___, 2017</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Number of American Depositary Shares: ________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">THIS WARRANT TO PURCHASE
ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received,
_____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise
and the conditions hereinafter set forth, at any time on or after August ___, 2017 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from XTL Biopharmaceuticals Ltd, an Israeli limited company
(the &ldquo;<U>Company</U>&rdquo;), up to ______ Ordinary Shares (the &ldquo;<U>Warrant Shares</U>&rdquo;) represented by ________<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
American Depositary Shares (&ldquo;<U>ADSs</U>&rdquo;), as subject to adjustment hereunder (the &ldquo;<U>Warrant ADSs</U>&rdquo;).
The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase
Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated February 16, 2017, among the Company and the purchasers signatory
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
&#9;One hundred Ordinary Shares for each ADS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrant</U>. Subject to the provisions of Section 2(e) herein, exercise of the purchase rights represented by this Warrant may
be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date
by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered
Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy (or <I>.pdf </I>copy
via e-mail attachment) of the Notice of Exercise in the form annexed hereto. Within the earlier of (i) three (3) Trading Days and
(ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the
exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price of the Warrant ADSs thereby purchased by wire transfer
or cashier&rsquo;s check drawn on a United States bank or, if available, pursuant to the cashless exercise procedure specified
in Section 2(c) below. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant ADSs
available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect
of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant
ADSs purchased. The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of
such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such
notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for
purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The exercise price per ADS under this Warrant shall be <B>$4.10</B>, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant ADSs to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.8pt; text-align: justify; text-indent: -0.4in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 75pt"></TD><TD STYLE="width: 0.28in">(A)</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that
is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of
&ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws)
on such Trading Day, (ii) the Bid Price of an ADS on the principal Trading Market as reported by Bloomberg L.P. as of the time
of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter pursuant to Section 2(a) hereof or (iii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice
of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of &ldquo;regular trading hours&rdquo;
on such Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.32in; text-align: justify; text-indent: -0.32in">(X) = the number
of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to
take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs
are then listed or quoted on a Trading Market, the bid price of an ADS for the time in question (or the nearest preceding date)
on the Trading Market on which an ADS is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of an ADS for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo;
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent bid price per ADS so reported, or (d)&nbsp;in all other cases, the fair market value of an ADS as determined by an
independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or
quoted on a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding date) on
the Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the ADSs for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the ADSs are then reported in the &ldquo;Pink Sheets&rdquo;
published by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the ADSs so reported, or (d) in all other cases, the fair market value of an ADS as determined by
an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 153pt; text-align: justify; text-indent: -81pt">d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Warrant ADSs Upon Exercise</U>. Within 1 Trading day of the date that a Notice of Exercise is delivered to the Company, the
Company shall deposit the Warrant Shares subject to such exercise with The Bank of New York Mellon, the Depositary for the ADSs
(the &ldquo;<U>Depositary</U>&rdquo;) and instruct the Depositary to credit the account of the Holder&rsquo;s prime broker with
The Depository Trust Company through its Deposit/Withdrawal At Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Depositary is
then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant
Shares represented by the Warrant ADSs to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised
via cashless exercise, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise, by
the date that is the earlier of (i) three (3) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined below) after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant ADS Delivery
Date</U>&rdquo;). The Warrant Shares represented by the Warrant ADSs shall be deemed to have been issued, and Holder or any other
person so designated to be named therein shall be deemed to have become the beneficial owner of such Warrant Shares represented
by the Warrant ADSs for all purposes, as of the date the Warrant has been exercised, irrespective of the date of delivery of the
Warrant Shares, provided that payment of the aggregate Exercise Price and all taxes required to be paid by the Holder, if any,
pursuant to Section 2(d)(vi) prior to the issuance of such Warrant ADSs having been paid. (or by cashless exercise, if permitted)
is received with the earlier of (i) three Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject
to a Notice of Exercise by the Warrant ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and
not as a penalty, for each $1,000 of Warrant ADSs subject to such exercise (based on the VWAP on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin
to accrue) for each Trading Day after such Warrant ADS Delivery Date until such Warrant ADSs are delivered or Holder rescinds such
exercise. The Company agrees to maintain a depositary that is a participant in the FAST program so long as this Warrant remains
outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period,
expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the ADSs as in effect on the
date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 31.5pt">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant ADSs pursuant to Section 2(d)(i)
by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise; <U>provided</U>, <U>however</U>,
that the Holder shall be required to return any Warrant ADSs or Ordinary Shares subject to any such rescinded exercise notice concurrently
with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant ADSs and the restoration of Holder&rsquo;s
right to acquire such Warrant ADSs pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing
such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to deliver or cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, ADSs to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which
(x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the ADSs so purchased exceeds (y) the
amount obtained by multiplying (1) the number of Warrant ADSs that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and
(B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant ADSs for which such
exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that
would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of ADSs
with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely
deliver ADSs upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this Warrant.
As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at
its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price or round up to the next whole ADS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and
such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The
Company shall pay all Depositary fees required for same-day processing of any Notice of Exercise. The Company shall pay all Depositary
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant ADSs, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">e) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise
of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the
terms and conditions of this Warrant and any such exercise shall be null and void and treated if never made, to the extent that
after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own
in excess of 4.99/9.99% (the &ldquo;<U>Maximum Percentage</U>&rdquo;) of the number of Ordinary Shares outstanding immediately
after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially
owned by the Holder and the other Attribution Parties shall include the number of Ordinary Shares underlying ADSs held by the Holder
and all other Attribution Parties plus the number of Ordinary Shares underlying ADSs issuable upon exercise of this Warrant with
respect to which the determination of such sentence is being made, but shall exclude the number of Ordinary Shares underlying ADSs
which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder
or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities
of the Company beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise
analogous to the limitation contained in this Section 3(e). For purposes of this Section 3(e), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act. For purposes of this Warrant, in determining the number of Ordinary Shares
underlying ADSs the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may
rely on the number of Ordinary Shares as reflected in (x) the Company's most recent Annual Report on Form 20-F, Current Report
on Form 6-K or other public filing with the Commission, as the case may be, (y) a more recent public announcement by the Company
or (3) any other written notice by the Company setting forth the number of Ordinary Shares outstanding (the &ldquo;<U>Reported
Outstanding Share Number</U>&rdquo;). If the Company receives an Notice of Exercise from the Holder at a time when the actual number
of outstanding Ordinary Shares is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing
of the number of Ordinary Shares then outstanding and, to the extent that such Notice of Exercise would otherwise cause the Holder's
beneficial ownership, as determined pursuant to this Section 2(e), to exceed the Maximum Percentage, the Holder must notify the
Company of a reduced number of Warrant ADSs to be purchased pursuant to such Notice of Exercise (the number of shares by which
such purchase is reduced, the &ldquo;<U>Reduction Shares</U>&rdquo;) and (ii) as soon as reasonably practicable, the Company shall
return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written
or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail
to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other
Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance
of Ordinary Shares to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed
to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding Ordinary Shares (as determined
under Section 13(d) of the Exchange Act), the number of shares so issued by which the Holder's and the other Attribution Parties'
aggregate beneficial ownership exceeds the Maximum Percentage (the &ldquo;<U>Excess Shares</U>&rdquo;) shall be deemed null and
void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon
as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the
Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder
may from time to time increase (with such increase not effective until the sixty-first (61<SUP>st</SUP>) day after delivery of
such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided
that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61<SUP>st</SUP>) day after such
notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution
Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the Ordinary
Shares issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially
owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. The provisions
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section
3(e) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent
with the intended beneficial ownership limitation contained in this Section 3(e) or to make changes or supplements necessary or
desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply
to a successor holder of this Warrant.<FONT STYLE="font-size: 10pt"> </FONT>&ldquo;<U>Attribution Parties</U>&rdquo; means, collectively,
the following Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently,
or from time to time after the issuance date, directly or indirectly managed or advised by the Holder's investment manager or any
of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person
acting or who could be deemed to be acting as a group together with the Holder or any of the foregoing and (iv) any other Persons
whose beneficial ownership of the Company's Ordinary Shares would or could be aggregated with the Holder's and the other Attribution
Parties for purposes of Section 13(d) of the Exchange Act. For clarity, the purpose of the foregoing is to subject collectively
the Holder and all other Attribution Parties to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Share
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise
makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable
in Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any ADSs issued by the Company upon exercise of this
Warrant), as applicable, (ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of shares or ADSs, as applicable,
(iii) combines (including by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of shares or
ADSs, as applicable, or (iv) issues by reclassification of Ordinary Shares, ADSs or any shares of capital stock of the Company,
as applicable, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number
of ADSs (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
number of ADSs outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall
be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made
pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record
holders of any class of Ordinary Shares or ADSs (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of Ordinary Shares or ADSs acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date on which
a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of Ordinary Shares or ADSs are to be determined for the grant, issue or sale of such Purchase Rights (provided,
however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding
the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such ADSs as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum
Percentage).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of Ordinary Shares or ADSs, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of Ordinary Shares or ADSs
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Maximum Percentage) immediately before the date of which a record is taken for such Distribution, or, if no such record is
taken, the date as of which the record holders of Ordinary Shares or ADSs are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, to the extent that the Holder's right to participate in any such Distribution would result in
the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such
extent (or in the beneficial ownership of any Ordinary Shares or ADSs as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Maximum Percentage).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transactions</U>. The Company shall not enter into or be party to a Fundamental Transaction (as defined below) unless the Successor
Entity (as defined below) assumes in writing all of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements, including agreements, if so requested
by the Holder, to deliver to each holder of the Warrants in exchange for such Warrants a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, an adjusted
exercise price equal to the value for the Ordinary Shares reflected by the terms of such Fundamental Transaction, and exercisable
for a corresponding number of shares of capital stock equivalent to the Ordinary Shares represented by ADSs acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Any security issuable or potentially
issuable to the Holder pursuant to the terms of this Warrant on the consummation of a Fundamental Transaction shall be registered
and freely tradable by the Holder without any restriction or limitation or the requirement to be subject to any holding period
pursuant to any applicable securities laws if any securities issued to any other equityholder of the Company are registered on
Form F-4 or any successor form. Upon the occurrence or consummation of any Fundamental Transaction, and it shall be a required
condition to the occurrence or consummation of any Fundamental Transaction that, the Company and the Successor Entity or Successor
Entities, jointly and severally, shall succeed to, and the Company shall cause any Successor Entity or Successor Entities to jointly
and severally succeed to, and be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the date of
such Fundamental Transaction, each and every provision of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead
to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Company and the Successor
Entity or Successor Entities, jointly and severally, may exercise every right and power of the Company prior thereto and shall
assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor
Entity or Successor Entities, jointly and severally, had been named as the Company in this Warrant, and, solely at the request
of the Holder, if the Successor Entity and/or Successor Entities is a publicly traded corporation whose common stock is quoted
on or listed for trading on a Trading Market in the United States, shall deliver (in addition to and without limiting any right
under this Warrant) to the Holder in exchange for this Warrant a security of the Successor Entity and/or Successor Entities evidenced
by a written instrument substantially similar in form and substance to this Warrant and exercisable for a corresponding number
of shares of capital stock of the Successor Entity and/or Successor Entities (the &ldquo;<U>Successor Capital Stock</U>&rdquo;)
equivalent to the Ordinary Shares underlying the ADSs acquirable and receivable upon exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) prior to such Fundamental Transaction (such corresponding number of shares of
Successor Capital Stock to be delivered to the Holder shall be equal to the quotient of (i) the aggregate dollar value of all consideration
(including cash consideration and any consideration other than cash (&ldquo;<U>Non-Cash Consideration</U>&rdquo;), in such Fundamental
Transaction, as such values are set forth in any definitive agreement for the Fundamental Transaction that has been executed at
the time of the first public announcement of the Fundamental Transaction or, if no such value is determinable from such definitive
agreement, as determined in accordance with Section 5(a) with the term &ldquo;Non-Cash Consideration&rdquo; being substituted for
the term &ldquo;Exercise Price&rdquo;) that the Holder would have been entitled to receive upon the happening of such Fundamental
Transaction or the record, eligibility or other determination date for the event resulting in such Fundamental Transaction, had
this Warrant been exercised immediately prior to such Fundamental Transaction or the record, eligibility or other determination
date for the event resulting in such Fundamental Transaction (without regard to any limitations on the exercise of this Warrant)
divided by (ii) the per share closing sale price of such corresponding capital stock on the Trading Day immediately prior to the
consummation or occurrence of the Fundamental Transaction), and with an identical exercise price to the Exercise Price hereunder
(such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting after the
consummation or occurrence of such Fundamental Transaction the economic value of this Warrant that was in effect immediately prior
to the consummation or occurrence of such Fundamental Transaction, as elected by the Holder solely at its option). Upon occurrence
or consummation of the Fundamental Transaction, and it shall be a required condition to the occurrence or consummation of such
Fundamental Transaction that, the Company and the Successor Entity or Successor Entities shall deliver to the Holder confirmation
that there shall be issued upon exercise of this Warrant at any time after the occurrence or consummation of the Fundamental Transaction,
as elected by the Holder solely at its option, ADSs, Successor Capital Stock or, in lieu of the ADSs or Successor Capital Stock
(or other securities, cash, assets or other property purchasable upon the exercise of this Warrant prior to such Fundamental Transaction),
such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription
rights), which for purposes of clarification may continue to be ADSs, if any, that the Holder would have been entitled to receive
upon the happening of such Fundamental Transaction or the record, eligibility or other determination date for the event resulting
in such Fundamental Transaction, had this Warrant been exercised immediately prior to such Fundamental Transaction or the record,
eligibility or other determination date for the event resulting in such Fundamental Transaction (without regard to any limitations
on the exercise of this Warrant), as adjusted in accordance with the provisions of this Warrant. In addition to and not in substitution
for any other rights hereunder, prior to the occurrence or consummation of any Fundamental Transaction pursuant to which holders
Ordinary Shares or ADSs are entitled to receive securities, cash, assets or other property with respect to or in exchange for Ordinary
Shares or ADSs (a &ldquo;<U>Corporate Event</U>&rdquo;), the Company shall make appropriate provision to insure that, and any applicable
Successor Entity or Successor Entities shall ensure that, and it shall be a required condition to the occurrence or consummation
of such Corporate Event that, the Holder will thereafter have the right to receive upon exercise of this Warrant at any time after
the occurrence or consummation of the Corporate Event, ADSs or Successor Capital Stock or, if so elected by the Holder, in lieu
of ADSs (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such Corporate
Event (but not in lieu of such items still issuable under Sections 3(c) and 3(d), which shall continue to be receivable on the
ADSs or on the such shares of stock, securities, cash, assets or any other property otherwise receivable with respect to or in
exchange for ADSs), such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other
purchase or subscription rights and any Ordinary Shares) which the Holder would have been entitled to receive upon the occurrence
or consummation of such Corporate Event or the record, eligibility or other determination date for the event resulting in such
Corporate Event, had this Warrant been exercised immediately prior to such Corporate Event or the record, eligibility or other
determination date for the event resulting in such Corporate Event (without regard to any limitations on exercise of this Warrant).
The provisions of this Section 3(e) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events.<FONT STYLE="font-size: 10pt">
</FONT>&ldquo;<U>Fundamental Transaction</U>&rdquo; means (A) that the Company shall, directly or indirectly, including through
subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not
the Company is the surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of all or
substantially all of the properties or assets of the Company or any of its &ldquo;significant subsidiaries&rdquo; (as defined in
Rule 1-02 of Regulation S-X) to one or more Persons, or (iii) make, or allow one or more Persons to make, or allow the Company
to be subject to or have its Ordinary Shares be subject to or party to one or more persons making, a purchase, tender or exchange
offer that is accepted by the holders of at least either (x) 50% of the outstanding Ordinary Shares, (y) 50% of the outstanding
Ordinary Shares calculated as if any Ordinary Shares held by all Persons making or party to, or Affiliated with any Persons making
or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of Ordinary Shares such that all
Persons making or party to, or Affiliated with any Person making or party to, such purchase, tender or exchange offer, become collectively
the beneficial owners (as defined in Rule 13d-3 under the Exchange Act) of at least 50% of the outstanding Ordinary Shares, or
(iv) consummate a securities purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with one or more Persons whereby all such Persons, individually or in the
aggregate, acquire, either (x) at least 50% of the outstanding Ordinary Shares, (y) at least 50% of the outstanding Ordinary Shares
calculated as if any Ordinary Shares held by all the Persons making or party to, or Affiliated with any Person making or party
to, such securities purchase agreement or other business combination were not outstanding; or (z) such number of Ordinary Shares
such that the Persons become collectively the beneficial owners (as defined in Rule 13d-3 under the Exchange Act) of at least 50%
of the outstanding Ordinary Shares, or (v) reorganize, recapitalize or reclassify its Ordinary Shares such that such modified Ordinary
Shares no longer have the residual right to dividends or distributions from the Company or the residual right to vote on matters
given to the common shareholders under Israeli law, (B) that the Company shall, directly or indirectly, including through subsidiaries,
Affiliates or otherwise, in one or more related transactions, allow any Person individually or the Persons in the aggregate to
be or become the &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, whether
through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding Ordinary Shares,
merger, consolidation, business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization,
recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary
voting power represented by issued and outstanding Ordinary Shares, (y) at least 50% of the aggregate ordinary voting power represented
by issued and outstanding Ordinary Shares not held by all such Persons as of the date of this Warrant calculated as if any Ordinary
Shares held by all such Persons were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by
issued and outstanding Ordinary Shares or other equity securities of the Company sufficient to allow such Persons to effect a statutory
short form merger or other transaction requiring other shareholders of the Company to surrender their Ordinary Shares without approval
of the shareholders of the Company or (C) directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one
or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to
circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition
or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or transaction.
Notwithstanding anything contained herein, any transaction which results in a Company subsidiary that is not wholly-owned by the
Company becoming a wholly-owned subsidiary of the Company shall not be considered a &ldquo;Fundamental Transaction&rdquo; and shall
not otherwise trigger any adjustment or rights under this Warrant.<FONT STYLE="font-size: 10pt"> </FONT>&ldquo;<U>Successor Entity</U>&rdquo;
means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity (as defined below)) formed by,
resulting from or surviving any Fundamental Transaction or one or more Person or Persons (or, if so elected by the Holder, the
Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.<FONT STYLE="font-size: 10pt">
</FONT>&ldquo;<U>Parent Entity</U>&rdquo; of a Person means an entity that, directly or indirectly, controls the applicable Person,
including such entity whose common stock or equivalent equity security is quoted or listed on a Trading Market, or, if there is
more than one such Person or such entity, such Person or entity with the largest public market capitalization as of the date of
consummation of the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be. For
purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum
of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or
ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants to subscribe
for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company
shall be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which
the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Ordinary Shares are converted into other securities, cash or property, or (E) the Company shall authorize
the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares or ADSs of record
to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such
reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary Shares for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of
the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Report on Form 6-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this
Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning
this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant ADSs without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial
issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute
Resolution</U>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
ADSs, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days
of receipt of the Notice of Exercise giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company
are unable to agree upon such determination or calculation of the Exercise Price or the Warrant ADSs within three (3) Business
Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two
(2) Business Days submit via facsimile (a) the disputed determination of the Exercise Price or the disputed arithmetic calculation
of the Warrant ADSs to the Company's independent, outside accountant. The Company shall cause at its expense the accountant to
perform the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business
Days from the time it receives the disputed determinations or calculations. Such accountant's determination or calculation shall
be binding upon all parties absent demonstrable error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Shareholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Ordinary Shares and a sufficient
number of shares to provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise of any purchase
rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this
Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant ADSs may be issued as
provided herein without violation of any applicable law or regulation, or of any requirements of the applicable Trading Market
upon which the Ordinary Shares and ADSs may be listed. The Company covenants that all Warrant Shares which may be issued upon the
exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant ADSs in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and
free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the
generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares and Warrant ADSs acquired upon the exercise of this Warrant, if not registered
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">k) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">m) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">o) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>XTL BIOPHARMACEUTICALS LTD</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;XTL
BIOPHARMACEUTICALS LTD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(1)&nbsp;The
undersigned hereby elects to purchase ________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(2)&nbsp;Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT>
if permitted the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(3)&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 15%; text-align: left">Name of Investing Entity:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 85%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 15%; text-align: left"><I>Signature of Authorized Signatory of Investing Entity</I>:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 85%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 15%; text-align: left">Name of Authorized Signatory:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 85%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 15%; text-align: left">Title of Authorized Signatory:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 85%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 94%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the
foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Phone Number: </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Email Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%; text-align: justify; text-decoration: none">Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 34%">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-decoration: none">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pg1img1_ex10-2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1img1_ex10-2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 70#O P$1  (1 0,1 ?_$ ,,   $$ @,!
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MMKVP@;1@7.].I,BZ(5&\SL=#MWB<8HMTO75*;YD)):+3((*'\NNNL4FNA!,
M%&*@<5Q__9[2.?TGLD )W(T^ 1X:K:8&[5N#N%7E64Y6;-$1\]7YJ-6*X8RT
M-*M$GL?(-%R@ *(.FJQ3%$=!\=! !U#B?)6-CV2L$L>H(JH%9Q[C^+<89H;[
M:,943(>Y3<:LB9P^Q;B%I$KC6DDVQ7JIKC:IV0C8"O&;LU2++E,HH9LF<!5
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MT#G#8L/P59G^&]431>[NE5E")))H8J4.HJ<I$TTDE;T8YSG.( 1-,GB(B.@
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M<"TF<>5BY9JQ34[)' @:0K]DR#5(2:8E<I$7;F=Q<E*MGS<JZ"I3D$Y  Q3
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MU;9]QI5K2?<*J7BKA!!,ZRZR:**:9U5553 FDDDF43**JJ'T(FFF4HB8QA
M -1X\WO;&*O( _+WK?W?Z8U>>"")OXR/4-R,26'PS7[%D9WA)S,3UTR+ QP'
MI,#!.V0(RT5ZLJ)#2RYEFR*VK<#$ $#&+SAJ)?DO>=U%G(V6.*:9S:NK-*T4
M$8Y5-*U\*KZ-VI;R8>2?^YO$ F:.AKMW'?2E::<"NG8/6:'N'Y1S-8K#D"RX
M31C6U#QQ8WY%*1#U3D*A&SS*#3*0LT\:O %NL9T*A2 "/,4P"73R[%M;++EY
MOWR2R6YI'"XU 9SIL?);'>=Q=85K/[>(XX+EM99FC4NX@Z5_S\%,3?8I=,>X
MKF,MT7+]XH$G7O;\0RJT,ZBR5B9,\E",11)'K1JCQ*5.W<F.4Z2W)R(  IZ
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M)KL&_<2RMNQOCVS3T8T<OXU^U<MKUCR<A73IN92/<6^L-BH]5(2J'74(7FU
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M/LX*3?<.V[([HMH&9<4-VB:]D<5M:TT4QB"=1O>J>(V"O CIJ)#R+AF9D80
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MA5G)@^U^6.CU5C!J(?:[*B8Y@U ?Z7'E]M;?_FS_ .H6?J3@4$CZ>:R/7:%
MX"HB442E$Y!43 42Z").<!,'2*( .FN@:!QZ_P!38.H/)037?5>=VA%2"0LG
MR$>]17)U19NR-G22Q"^(*BW7!0AR%_VV@@'&$D;'GYF-=Y@("YIJQQ:?!?&2
M<0P;)(1J,>R:&,8$$F2;9LV,<HFY^@FW!-(Q@Y1UY0^@>/".&*,]4;&M)Y !
M2]SW_6XD\SJO0F^9JJ DD]:JJ&_933<(G.8=-1 "%5$PZ!X_3CUJ%YT?Q(IY
M+M7<-VI#K.ETVZ20%%19=0B*! ,/* G44,5,H:CIXC]1#A59UTH-DCNFP)@J
M==%-(W*)53JIE2,!@ Q1*<3 4P&#Q 0'00^G$+$UIINOB;E!4.9)=)8G-R\Z
M)RJ$ _XE$Y#&*!@_$/PUXFH4#KK5Q!'DN +MB@<W50)TU 04-U4QY%1$ !(X
M\^I5=3!]H^/C].)J$^<C6@=[UZ!* @'/]Y3"'@("(:C]!T$1^G$&G! '@_,:
MCR72BY:O"CY5RBX(0YDS';*D6(0Z>A3IF.D8P%.7F\2B.O &BEP)^DT*[C""
M91,=30H!XF,(% H &HB)A$-   ^NO"HY*&AP-7&JZ0<MQ$ (NF(F(*I=#D$3
MIAH JE^\!.F'^V#P_GX5"EU?XT"^>8:F(0YG")DU="I'!4G(J)_V2)FYQ*<Q
M]/  \1X5Y*&@@]3J$C;1<A5;D."?4(50Q1Y4^<O5$A1*!A G,!A(43!J(!X"
M/"JR-3J-*KB#EL82"5<ARJ#R)F!8@IJ' 3?8F/.)5% $HZ@'CX<*A15PTT*0
MN6QA(8'"8<YQ2((*)CU%"";5(@@;[U $!^T-1#^3@" H<''9Q 7$SYF0.91X
MW(0#F2%4ZR)" J7]I$3"< !4/Q+]0X5"EK::NU<NP7"!2D/UTRD4$@)F%0O(
M<RG]65,W-RG,H(^ %U$P\*A0[K)T('L7 [IHDLF@JX1(Y7UZ*!UB$67Y=>;I
M)'/S*\FGCR@.@\*J0"-="]<A<($,<AE2D,0G4.45"@)$Q_W0Y><!3)_Z0@ <
M*H>HZUHNHSV.(;4[QFF<2@IJ9RB0PD.4#%4#50!Y#A]!#P'@IVUW*])12T*L
M42FYP^Q0#<_.4WB E, B!@, >&GX?S<-$/,;KB4Z2X"4HD5* F V@E.4ITQ
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M3Y]/Z?!$WUJ_2G^FNN^K_* 4+YE=>QPC??HYB^:/>-AT]J"EI<?7/7//>7Y
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FL^M?'7LOTF"]6U\E_D]Y[T7ROD_-_O'3Y^GX\_!%*?@B7!%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pg1img1_ex10-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1img1_ex10-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 70#N P$1  (1 0,1 ?_$ ,4   $$ @,!
M      D !P@*!08" P0! 0$  @,! 0               08" P4$!Q    8!
M @0% @0#  L*#P   0(#! 4&!Q$( !(3"2$4%187,2)!(Q@*43(D87&1H4(S
M1"6V=SC1=+0U)D9V-[<Y@;%28I)#-%6UEE>7>!DI$0 ! P," P0'!04'!0
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M5?0K1^JY>0TY%=8BKAB99<AT3"JD?E(<A(!TH5LPN=;DAY$PI<#V_@C6\0K
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MRY-KG;&\EDA94-CXG0'11QR+^X'VU4^VI1U:P_FF]T%1X=HED]M&QU9A)I-
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MVS:HWP,8V3<OAV'O0/BQ:M?>76)*LSDC'Z0,)!V1<\='/"J_:9)PLD<I_M$
M'@330KR'*8\2F$S,\T;BJE8@X;N44W#=9)=NJF19)=%0JJ*J*I 43525()B*
M)*)F Q3 (@(#J'AP&NR]U13F!^%--E[<!A+ ,(VL>:<IT?&4.^5,A'NK?8&$
M0:37( "=&+:N%0>R:J91 3%;IJ&* ZB&G$T*TS7-O *S/:T'M35US?=LWMU=
M=6FM[EL.S$0R?1D8Z.SND4>11D)F1;1$4S-!&6).BN_DG::*90;")CF_@ B
M D5&RTC(V)',)64K3?BLWO-\=HNYO_4/E8! =!_YE36H?P$. 6=\/\I)_"4%
M7]N<\9QVV_<6_D';9BQ997AW3Q\]<)-FK1JA0(Y1=RZ<KF310013()CG.(%*
M4!$1TXENZK'2@++*X>_1CI-"=C2H*,K3M\^SS(%]3Q?2]R6(;)?5G2C!I7(N
MY12[J1?I")3LHE?K%8R[OF 0!)LJJ<P_0!XP)%:<58H\E8/D$+)F&4["JE8
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MXE4J$K"3N1*C$R\8N=,JQ$9"-?RZ#UDJ9(X& JA"F$H@.F@\.4HZY@8\1O>
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MLK-USM$'CFC6>Z39TXZMT6L3%FECIE3(FUA*W%N)-X5%/[$R FR9F A0T /
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M^P"HLL4G2]I()?AR[JL &O+&10NKMK7Q1*@ H (!J&OT ?#Z?0 #\ XOQ<T
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MBJ5TP0,A/7_$/O*-]W8?^[KW6?ZND/[UIKW^[Q!5JRQY<?.YVWEGVZ**_8"
M!V"G ?\ ZX90 ?\ T*[PUJN9TL"S$,#OF#G>^J\F_+M183W\RUBS3A:_Q%%S
M8S?2-0MDPW2+/4.XV&FJF@GD/=HUH<KZ'M$(JT!FL]:\RH%3 JR"PE 0P>TN
M.FZ9+ V^1D^K@>6W(%.X\?6@O4O<1W%>SSDV QQFAE,VG#CEP8S>C6&76M6/
M[574%$RR3[$MW4ZSBO2S- Y3E:E,@5(XE!RST, @;5HH57XKW+82X$-ZTFS)
M^8D'4Z4WKPW]JM*[@+Y7LI; \RY*J3H[RKW[:]>;A7W*I2D64B+%C>1E6(."
M%,8J;A-!T!%"@(\IRB'&?%7:ZD;+8.D;\ICJA+_MPO\ 9[W!?ZWX+_0.,X#<
MJL](_P"EN?YB<#]Q$(#L\QI_8SY70'^V%0N6O_CX@A>KJQI.-:P?,7BB('L#
ML$-5.W;MHM%AD&\3 5S;[6IV<E'9Q3:QL/$P2CZ2?N#A_*BT9H'4-^.A?#QX
ME=JPD8W'1O<:-$8KZ/W* V(MT6YGNIY$R#$;>KK([6MG6-IA"#L&485@R>YZ
MR<]>)F<MH>L/90KJ*H:;Q@3S)U445'+%NLESJ'54Z9 [ER;>_N,Q<R0VHY;.
M-Q:7]NO#CW]B%WWP-L&(MM4KMA9XUB9LTS;VV17MYN]QM$]=K[>9*.D:>1G(
M6JT6)^_>OEVP/%>F1/I-TNH8$TR@/$E<'J>QCM9;7RW%SP^IKQ&]5<,I8_\
M(ZI_]&H+_P"%M>,5?XG!T;2.+0?8JI/<PAW^Q#NE83WG5=HJTI^2I.&N-D(T
M*=)LYDX,S:G9=B%!+H4RT[4'B#T0UU.JN<WU#B3HJ7E8Y;#.MO8Q^BZE3[]/
M:B@YZC*WW"=Y]"VU*JIV;;7MSQT7.6:C-CF/$6S(N5*\[B<,5-99,1144A:U
M*K3O(/B *%U ! !":+MW(9E;GZ-M'6K6U)':1I]N&J%?VH,M*;#=Y>Z3:%F>
M9]'J8MKD_%](*E1:DL6'&<E/M)M RYB$$EOQF"RQ-! 5S(H%*(CIK TTXKC8
M6\.-NY;6X/(QK2=>[5&D[6=5F[#BG(^[:\,E&M^WH95L&9CIK\P.8O&:*ZL#
MB.N""A0.FUCZHT!PF0!Y='8" <%WL2P^3)=N^::3F'>#L??HBC\0NPEP1"+[
MG.WNZWQ&GY;I<0_L1*G$/ZY:8F)04>2;6(6>&DF,XV9(%.Z=-VBZJR;D$BF.
MF4Q#\HE PA\M_P"2<!<9..WR-L"X0.^*FX':!Q]"OW0V7M[!SL=<OY1(:BNU
M=J56"V[=S&EP-%AJ7G*,M#2T56.;0J-A@XGU="?;1R(-F9G[$%F[^/F2H)%3
M5 2'(JH GU*)A )PO7<<=L(LFR9L@TTC>[;P"C,]&RNNW2XQ\3X7&NKVM(/I
M.H6UY-<WCN"1D53*3B=]CW%49+DG#YFRI&*M)H54$E$RM:+7&ZY7*@2!3<C@
MQE3I&2_F$HE#C=E#=];-_I\=L^.P&TS@6FO\)U]B\V.%OT?+];).'WYT,3?B
M ![7#X:J%E.O.XWMVW^3KUDKJDQ1I9YU7<8[4>&IUI*GH1"PU2>2251BI<6Y
M !0HE%3Z$72'E*8M3M)NI.A+HVAK<6!.U*U\*;55PN[?"]8VK;B.9K+\#6HI
M3QKOX>I334[A=GRI"I)XEQ!DV&:HR4.G=\@-J@^R8E2XAP\2*]/"U>GQTD_L
MDTZ3 R*!!(4B0GZBA.4!$+_CNJ;G.21PV%DX?$/,<XAO(WB17YJ=@U*HE_T_
M%@&/N<I<M=&&DL:P%Y>1L/A&E>] %[A5;W+[E=\SK</C/:3N3<46M*8Q95?U
MW$=LB)&>:X\4:R+AZNP48F6CT923%8$2JZ*E2Y1.4HZE"[/;7D _*=5\/S)O
M+^_=-' _R 1RDM(V\=0K:V#-Q,!G=D<&&/\ ,F/YAK#,I68@\KXKM] 5CU7J
M@HJQK>5FXUO!S3UJL4W.#%RX#I@!]>4>-GBK_!="8!\8)^$;BGCO^"#=WI^V
M]-YFC66ZO;[57\IF2I$C([(-6JK59:PWZMM%T4H6RPK5D7S;RY4Y8Q=>GJNX
M8 &@\[<@#'@JYU#B3,YM_;<WG-W#1J:Z5I[UONS#?GGV0Q:RQ#OCVD;FT9=C
M!*55UE"&PC<;3 7ZO+,C1ABW6'C8XTS'3RL>84W;AN@X;O1$5!*D8Q@&=_%;
M,;D;E\/TE_'(W2E>4[;:H/>9MI.];M:;B'N<MJ\;=)O$KY5V[IUPKU=?6MB2
ME32J;[XYS!3T&RCMN>+*)$1.X1(FH9 CA)5)<H@2-=UPKRPO,)>_58\/="X;
M 5U/:%,O&_<;[KN]\B6'<*8 J.)WT\5.'M&>0J5Z8Q=$BW)/*RMA3?7)T:%C
M9%% YU$$D2/'O4$H(I\_*H"O8O=!E<YD1]$RW+ 1\3R>6C3I45W/<-4<BJ1-
M%V";:\>T./@LI9#C:=&GB/\ D'1+#D.ZW>X/RR%CL5BEF%>:/UVSVV3ZCEPJ
M[>'(W367*118/ >)KHK+"(L5:LMSSN:*_$ 22>^E:>Y5T>UL;.&U_=_E_+.9
MMK&Y2O4/,5>M\?ZO&89NT^XK,A+7EM<8P)",BXMU(.&:B1#MU%$$U134Y3"'
M((B$#<JKX.&:TNY9;ACVL<\D:'4:HQG=7RG*V;:=E#!.-L09RR;D/+U+KB,*
MUIN)KI*0<3&2TW&2SE]8;$G%!%1KZ.CXI0%& JB](NHF4Z0 (B$GL7;SMSYN
M/DMK=KW3/:*4:3WZFE HW]D^W7?"&%5=M.9L%9[QO;Y#*UBL=9G)_$5T1IDK
M%V2-C%CC(6<D8K&5Y=BZBUB'\Z=!,P'3Y#&$P@$<%Y>F7OAMOH[EKVS;@%I[
M.W9:%@O=]F'9[N?WC5O,V LZRNTZ_P"YK)MHJ65ZIC&V6)C2[$[E"(RSDJ#"
M/44EZ;8&Z*"QUFW.=%P43I J"AP!MJHM,G<6EW-%<QR&#S#0M:7>[W+O[AV2
M(_NB4;&NV?9YCB_9%G39,@K?9<QV;&]NH6.<3P3*-E6+\92RW.'A%G+V33DR
MBJT:E.H=%#E #J&*0!U49:5N8B;:VC'^9SU/,TMH/$T4Y=S3M#;#L7=;5*+C
MS,.8KBKMN>8FH[/'N-+3:6DB[-5QI@RMBGHB/<05=(+I4[Q1)PX!<4?Y"G$0
MU+I7!9:67T0#W/\ +IHTD>L!#F[($IDO:["Y/P[G3;]N%HR^1K[4YRG69SAJ
M[NZRJN>*)6G["?E&<4N2O$;*$;K@Y<@1J"(J"90O)H(=JXO30=9QS07+7-DD
M?4"AV6_=[^;OVX/'54V_85P)GW(5AJ.6 LULL4/B.Z>SX]M"P,M%H-X>P+12
M;&S*2+J7U*HR,L@1-,PB?42AP.RSZF=-<M9;VS)'/8[6C33;@>*D1M,/8<Z=
MN@^S&SXVS)AS+K/;7:<62'R'C2VU*L@^+%O*]#R43;WK D(_0?&?-E!0*N#P
MJ?5U2T()A<%T+%YN,2+%P<VXY"-01KXH.';FW5[ANVE;\H;=<K[4<RWI"X61
MJ_;5>HUJ2"U1EZCVQ807,"HI&K0MDK=E8MT>51%QH I$43,8HG*(+AXJYN\/
M(^UDAD='S:D FI'&M#59GO&UW>SF:!P+G[+^&DZ#3G+BWP%+Q)4F4I>+GC%.
M0"%DV+O+UCB6QVHV:YIM0%)FU0(V8 T%$QC+G/Q)4YR&\NFMN964%#R@:D Z
MZ\?0=E8HV+99W(YNH;+(.9,0)X'I!Z73H.@T2><+O<CS\G',3$L^0+&4[6/+
M7*_-*@BG#QBB .P1(=9<0YTPXCBK9CI+B6W;Y[.0<K::U)TW[DP'>EVW'W ;
M)[=+044K)7C"+Y#*U729M5'<D[CXI%1C<X=FBD4ZRIGU9>++@F4HBHLT3#34
M X$+Q9ZU=<V);&*S@U'N6X=I7;"]VY;1*BZN3=X.5LQE9Y0R&ZE#KK3#492*
M:,J;5WB[DYG(%JM-;-&X(FT!!8ZI2@ <2%G@\;_3K8!Q+ISJ24+KN^[ [-ES
M>]MBM^/8J1!EN7D(C$V2):+;.E$8&3JO*9[991RU3$C)%YC95<@J*B4JHQO(
M(B)].(*Y.=QYFOXI8@1SO:#0<*@'V*S-4ZQ#TJLU^GUYFG'5^JPD578)@D
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MW!3I"J05S%$X(]0.H8@::J%2,83"0/X@&G"J"HU%.;U+[UTB\P"<"\NG-J8
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MM_7X/)&9<C;K7%S/>F$NM=X>-+8K<S07K3$"RM?C6KFS1B1$W:IB'!,"E)J
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JQ'5.;J^K?'WL'UZ2]+]LZ?\ )KU?U3G\UT/ZCI=/7\OEX(G^X(EP1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !X /4# 2(  A$! Q$!_\0
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MV7^V;""^\G?O\KS(U?;NP,XSC.!FO#/^"GW_ ";WIO\ V'8/_1%Q7K/[./\
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M%X5FD>ZT$WGVI;JRW[$NX)"B%E#$*Z[<HQ7LZFNX_P""7O\ P4'N_P#@H?X
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MQKB(ZA%:317B#_:)$4S>IN,^M?LG>WL.FV<UQ<31V]O;H9)99&"I&H&2S$\
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M'OR<,,@Y#$5C#+*53W(U9\TIN+O:UXZW>MWOIUN+V:?5[V/H_P !_P#!(_\
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M%LGJ]MK;)K0YZEXR<;A1117G&84444 %%%% !1110 4444 >;_M2?\D[M_\
MK_C_ /0)*^?Z^@/VI/\ DG=O_P!?\?\ Z!)7S_51 ^F/@5X<A\/_  WT]D0+
M-?)]IE;NY;D?DN!4'QG^+$GPSL[-;6WAN+N\9B!*3M15QDG'/4C]:Z7P; +7
MPAI<8Z1V<2_D@KQ_]JG?-XKTF)59F-L=J@9))<CC\J%JP/3OA7X]_P"%B^$X
M[]HUAG61HID4Y4,,'CV((-5_B-\.+7QOK.ASS1AOL=U^]X^_%M9MI]BRJ/\
M@1KQ7P=XL\7>!-/DM=-M;J.&63S6#61?YL =Q["O0O@W\0/%'BCQ<UOK$<BV
M:V[OEK3ROF!4#G ]30!ZH!@5Y/J7[4$-AXNEM/[/\S3H9C$TXE^=@#@N%QC'
MMW%>J7<OD6LC_P!Q"WY"OCQFW,2>I.:(@?8J.L\2LN&5QD'U!KYA^,7AB/PE
M\0]0M88Q';LPFA4#A589P/8'(_"NJTW]J+4-.T^"W_LNT<01K'N,C9; QFN,
M^(WCV7XBZ^NH36\=LZPK#M1BP."3GGZT(#RSX:?\GW>&/^NR_P#HAZ^ZO&GA
MB+QMX.U;19Y)(8-7LYK*22/&Y%D0H2,\9 ;O7PK\-/\ D^[PQ_UV7_T0]?7W
M[5GQN7]FG]F/XA?$1K,ZC_P@_AR_UQ;7./M+6UN\HC)[!BH!/8'-?7<1QE)8
M&,-W2A;UNSX_A&[K8ZW_ #_G^2/%_!/_  21^&_AS_@F[#^S+JEQJWB3P;;1
M7(M]1O#&FHVL\MS+<QW,;(H598I9,H0N/E 8,"P*?L_?\$L="^%'[1TOQ4\8
M>-O%'Q;\7CPI;^#K6Z\4P6DOV2RAD#A@$B7=*S#+.<EBSD\L2?B+P%^RNWQ;
M_8"TG]IC]H']JSXG> ?'_P 0X%UC1M9L/$\FGZ!X6>YW/8VT=H@VE,!2Z KG
M+*""-Y[[PU^T/<_$?_@L!^Q_'H/Q8N/B5X9U;X=:W'?ZU8.;33O$UY;1WT4E
MRUM&1$'$L1XP=I7@\5G4P^)M54:SE\;D^5VYDN:23M;6VMK7MM8^Z<9:Z][G
MOG[17_!%3X?_ !Z^(WQ6UZU\1^)/!MO\9O#-IX<\2:5HZ6Z6-PUK/#+#>*C1
MG;.HA6//W=K/QEB:] _:#_X)B_#7]J#]B+0O@;XRM[K4]$\+Z19Z;I&K?(NI
M:;-:VRV\5W$^-JR[5^88V,&92I!Q7@W_  44O]4\0_\ !8G]D7P3'KWB#2_#
M_C#1O&=GJMMINH2VHN%.DN%<A3@NA)9&()5@".17S3\2O^"<.B>%?^"S?PY^
M!=K\4/CQ_P (+XH\ 7?B2]#^/+MKS[7'+<HNV7LF(D^7;Z\U.'IUJD*<IXAQ
M:BZBLKV4;QWNM;15O+044VE>72_]?<?HOXC_ .">/AOQ)_P3DC_9KEUS7(_"
M\?AFW\,#55$7V\PPA LGW?+WG8,_+CD\5TGCO]B'P%\7?V/++X(^,M-;Q-X,
MM-$L]$(N6V7#"UB1(9U=,;)E,:N&7&&[8XK\F?\ @HWX\^(/_!./_@JQ\*5^
M&NO>.?$G@WX,_"^T\2:]H^H:[-=S:SI2ZK?Q7SRACLFF$$Q(=QE1$K9_=@5'
M_P %9?\ @H_XR_:P_:E^&\OP=\2:E#\"_A_XK\.:?JVM:5>26L6MZSJ;&=;<
MNA'FK%;1E6CZ([2!N2E;4LEQE65.5.K[LKSYMK2_S>EM?R&J,W:STW/N3P'_
M ,$+O"=MXR\*W/Q$^+?QD^,WA?P'<I>>'O"OC'6DN](LIHQMB>6-8U\YHUX7
M<0N,@@J2I]K^''_!/WPK\//VP/C!\8/[0U+5M1^,^GV.F:QI%XD3Z?##:VZ6
MX"#;N(=%^8.2#D]J^-_^"VOQ.^)'[0WQYTOX/_ _Q/JNB>)/@[X7O_BOXFET
MRY:*266",+IFG_*1ODE=G8Q-P5>-L&J7_!83]L'6_P!H?_@C9\'?BA\*_$E]
MH&M^.O%6@/;76F7KVKVMW)'<++;NZ'.([A2C*<C,?(.*QCA\=B%2<ZO\7W7I
M\*;NKI?S6YM-787+.5KO<^TOV!OV =#_ .">/A'Q-X5\'^)/$6H^"]:UB76-
M+T34VCEA\-F4DR06T@4.8C\O$A8@J3G+,3[Y7XF_MS_\%2O&/QQ_X),^+O"?
MC&;5/AK^TE\+?%.D:9XPTNSEDTZ>5#=;4O;<HPW03+MW;&*AF&/D>,M^U6DL
M7TNV)Y)B4DGOP*\W-,%B*5J^)=Y2<EZ\JCK?JFI)I]=^IG4C):RW+%%%%>.9
M!1110 4444 %%%% !1110!YO^U)_R3NW_P"O^/\ ] DKY_KZ _:D_P"2=V__
M %_Q_P#H$E?/]5$#ZY\*R>;X7TUAT:UB/_C@KRK]H&XCL_BIX9FE98XHO+=V
M/10)LDUZ)\*M175?AQHLRMN_T1(R?=1M/Z@UY_\ M2^&+J^.EZA;P2310J\,
MI1=VS)!7/UYH6X'J&@>*M.\4Q2/IUY#>+"0KF-L[2?6M"O.?V:O"UUX?\(75
MQ=PR6[7TX=$==K; , X]R37HQ;'X\"I AU(;M/N!ZQL/TKX]K['9=ZE3T(P:
M^1=5T.XTWQ!<:<T4AN(9S $ ^9FS@8'O51 NQ?#CQ!/$LB:+JC(X#*PMG((/
M0]*S]7T.\T"Y$-]:W%G,R[PDT91B.1G![<'\J^MM'M6L=)M86^]#"B'Z@ 5X
M%^TU?+=?$KRU.3;6D<;>Q)9OY,*$P/"/AI_R?=X8_P"NR_\ HAZ^Z/''@O2_
MB3X*UCP[KEG%J.BZ_93:=J%I+]RYMYHVCDC;'9D9@?K7PO\ #3_D^[PQ_P!=
ME_\ 1#U]M_%OXHZ-\$/A9XD\9>(K@V>@^$],N=7U&<+N,5O!$TLA [G:IP!R
M3Q7UG$G,XX)0W]E"WWL^.X1_C8ZW_/\ G^2/@'P!_P $O_VJ/V;_ (:WOP=^
M&?QV\ ?\*7DDN$TF?Q'X;DO/$?ANTF=F\B @^3*5WMAY",$Y54&%&-\.O^"&
M7Q"^#_[*O[/T?A'XB>%_#_QX_9\OM7GTS6_L4MWHVJVVHW,TDMI,C!9 NR0#
M<%)&90!\P99/@W^T1^WI^VE\#&^.G@&+X1^"_#-\LE_X5\ :KI\MS>>);%22
MC3WF\>5)*!A"IC5N"?+4AJI_M2_MV?M(/^W]\/?@_IOC;X9_ 2XU[X66WC#7
M$\0V\&KV=AJ1N[J&:V2Y8H'R(T"X./D)&<YK;FS!S=-5*=TVY62W2:?-:.MU
M)IV35[]3[WW[VNO/_@GL_P"S1_P3T^,&O?MLZ1\?/VB_'W@[Q1XJ\&:-<:+X
M4T7PCILUII>E+<!EGN&:;]X\C([K@C^+KA5 [CX@_L*^(/%__!6GP%^T'#K&
MCQ>&_"?@BZ\+W&FOYGVZ:>66X<2)A=FP"9<Y8'@\5\M?MQ_MG_M&?L-?\$Z;
M[Q\WQF^&'Q,\4:AXVT_1M.U?0-"A^PV=M)#,9H70.ZM)O5&SG(''>MWXX_MG
M_M3?\$K?%7@?7OCIJGPV^+7P@\7:[;Z!JFL:%I<NCZGX9EF)VRLF6C>/:';&
M"6,97<A*EN7ZMC:C]I"<+R4H12TNDM5%.*77K9MLCEF]4UV/>_'_ /P3VU3X
M@_\ !5ZQ^.U_?>'[SP0OPSF\!WVAW"2/=7;RW,\KL5V^682DVT@MD\\8KS?X
MV?\ !$30=)_8U\ _![X,W=KX=TOPG\3;'Q_>3:[<27$MZ(C+YJ;XTRTFUHT3
M( "Q*"<C)\JO/VSOVB/C?^W-^T#X'\-_'SX/_"7PW\*=>MM-TVV\4Z);RS7T
M4T3/E':1"VPH<GG[ZU=^.O[37[57A?\ :D_9Q^!/AOXO?#>Z\4?%'P_K&K:E
MXLC\+QW&F7GD-<W,#PQ!CA?LT:1Y5L,WS=ZTIT,?"4(JK%<L4[>]9*,7)-^[
M9V3>UWJ/EFK:_P!6.L\#_P#! 'P+\;?C_P#&#XG_ +3&FZ+\2O$WQ"\1F^T:
M#3M4U&TMM"TU$"0P;HG@:20($1BP( A3;C+5P^F_\$)?B/X5_94UKX,Z3XV\
M(MX+T_XOVGC_ ,(+<O=M-IFF1M+YEE*?+/[S'E$$%E+&4DC(S8T[_@IG\?/@
M9XG_ &I/@_\ $J^\#>(OB!\&_AA>>/\ P[XKT+3V@M[G9;I(D=S;,S*&#31$
M+A<A&SN#*U>4^+/^"DW[5'P>_83\(_M!S?'+X)>-/[7CTJ\D^'J^'XH-4NQ>
M2QH;56BE\PRKYF2%4$*CM_#@]5*.;2:7M8V;@HIW<=KQY59I:::V\RE[7OVM
M_P  ^EO^"T'_  0ZT_\ X*8WWA_QAX2U;2_!_P 3=%:*SN;^\20VFLZ>K%A#
M,(P2'C8[D<*>,J>-I3[]L8#:V4,3<M&BJ2.^!BOA;]I']M[XV_&[]L^W_9W_
M &?+/POX5\0:+X;MO$OC?Q7XFMVO8_#27 5H;2*W4@27!#(?FW*0_1=K,//]
M3_X*5?'?]EJX^.'P?^,Z>$KCXG>$OAGJOC_P#XQT6S,>G^)8;6WE8^=;.2$F
MCD0DH JD1.,8VN_DRP>.Q&'IT9S3Y5>,;^\HR:UVVV=KW2UM8RY9RBDS]+J*
M^:_V4?VFO%?Q:_X)3^&_BSK-Q:2^,M3\!R:_//';+'";L6TD@81CY0NY1\O2
MOS9\;_\ !<K]HC1/^"5O@7XKZ;?:!?>.]>^):>&)4&B1O%=VITB&Z$*Q+T=I
MG/S+\V#@5S87(\1B)RIPM>,N5W?77RVT)C1E)V7H?MU17YU_MP_\%R])^&__
M  2I\(?&#X=M:2^/_BQI^/#.DNOVLV-Q$,ZB\J?Q)9[)58D8+A,\,:^IO^";
M?QR\0?M+_L'_  K\?>*IK>X\1^+/#]OJ.H2P0B&-YG!W%4'"CV%<U?*\11H?
M6*JLN9Q\[K?Y=/44J<E'F?H>W45\V_LJ_P#!05_VF?BK::&W@W^P]'\1:/J&
MO^';\:U%>7=S:65]'92&]M%16L9&DE!1"TF=DJL4>-DKT?\ :9_:2@_9XT#2
M$M= U;QEXN\57O\ 9GASPWI;Q)=ZQ<B-I7^>5ECBACC1Y))G(5$4]6*JV,\'
M6C4]E)>]ZK\]M-;]NI/*T['I=%?.NF?MV:UX$\"^*M0^+/PF\6_#W5/#:VAM
M+2RN(=>MO$KW<WV>UMK"YAVK)=O.5B,$BQLID1N4.\2_"?\ ;3\67WQ0T/PS
M\4O@_KOPG;QHSQ>&;^XUJSU>TU"X2)YC93O;G_1KLPQR2+&=Z.(Y LA9=IIX
M&LDW9:>:UTOIKK9:NU[=0Y&?0M%%%<9)Q/Q[\(ZAXT\&0VNFV_VFX2[24KO5
M<*%<$Y8@=2*\?_X4#XM_Z!/_ ),1?_%5]+44[@>5_!72/%G@ MI^H:/))I<S
M[PRW$1:W8]2!NY4]Q^/U]4SQ103@T@,&\UG6I/%=C;V^DR)I>YOM=S+)'DC:
M=NU0Q.-V,G&?:CXCP:G/X88Z/'YVH0S12Q)N"[MLBD@DD#& :W@<FB@"OI=U
M+>V$4LUM)9S,N7A=E9D/IE20:&TNU:\^T&WMS<#@2F,;Q^/6K%('!/44 ,O)
MVM[622.%YW525C4@,Y] 20/SKY[\3_"'QIXJ\07>HW&D_OKN0N0+F+"^@'S=
M ,#\*^B,\T4 ?(/@?]E_QQH_[6>@^)KC1/+T6SD5IKC[7 =@$3+]T/N/)'05
M]'_M ?!G2_VC/@7XQ\ :T\\>D^--%N]$NY(3B6**XA:)G0GC<H;(SW KKP=P
MHKTL9FM;$^R<K+V45%6[+9O5Z_U8\W+<KI8*56=)N]2;F[VT;MM9+33K?U/R
M\_9O^-W[8'[!?[-MK\!+C]G'4OB1XM\)VS:+X*\8:3J5NOAV\LUREM+>LSAH
M?*7&48HSJH!V'+GS_P#;3_9^^*'B/_@I#\-/B=\7/V8V^/6FP?".WT;Q#I7A
M:S2]T>UUDW][*1$;H_\ +-'4\Y/[S@D<U^P=&[!Q793SSDJNM&E%2E>[3DF[
M[]=.^EM3V/;6=['X[_M[?!GQ5^T[_P $L;[P/\)?V2_&GPAFT/X@:9JT?A==
M/MH7U-3#/YUU&D+;<+MC5B><E:[S]L'PS^T)_P %I)/ _P ,YO@;X@^"/PFT
MOQ'::YXMUKQ=J-N+V^B@)Q;6UO$68G:SD-R"^S)0 [OU,HHCGTHI.--7BVXM
MN3:<DDWJ]7I=7OJ'MK;(_&OQ-^SO=_#?_@HA^TIXD^(?[%OBKX_Z)XX\1VMY
MX9U2+2K2YAM88X664H9SG$C,GW?^>?/:NF^-?[$>M?\ !0G]M']E.^U/X+?$
M3X3?"?P_X6UG1=6TZ"?^S+CPJD"7*64)EMV_=+(8X=JJ>4<*>IK];J*K_6&J
MFIQC:2CRIWEI[O+=*]D[:Z+<?MWO_6UC\=_A7_P3K^('['EE^V]\)[/X<:]X
MOT[XG>"]2G\">/-C7U]JJ/9S)'H]S<%B1(I=0H*IN>-B20\0'D/_  QYKGB/
M]@WP[\-?"O["/C;P_P#'JUTW3K2'XB2Q6>D"SU*&2)GU#[6LHE4Y1B-V,D\U
M^\U%:QXFKI\\HIN\7>\E=Q5M;-73MJMA_6'N?FAK_P "?VAOV /VO]+^/NB^
M#9/CM#X\\!Z1X;^*&F:+=1Q:NFK6-O%%_:%HDFT3(WEJ-H&3E\A<J1-X"_8U
M^*'_  4S_:M\<_&'XU>"[KX0^#KGX>:A\.O!OAJZN8Y]9\F_25+B_N@A*QMB
M64",X/S(,83?)^E-%<G]M5+74$IVY>97OR]K7MMI>VVA/MG\S\E?A1X[_:Y_
M9H_8+G_9;7]FO7O$WC?3]+N_"FB>-+/5+4>&I+";S(XKN20L-K1QR?ZMMI.Q
M2VTDK67^TA_P2-\=? +]A[]F7X>^#]&U#QMK?AWXJ:)XH\5MI<9EAL3'816]
MU,"<'R5>$88@'##@5^OU%;1X@J1GSTX1C=N4K7]YM6ZMV6KLE;</;N]TO,_,
M'XK?\$'M+^&OB/\ :B^)&@-+XD;Q3X-\01_#?PA;HQ3P[J.IZ=,E]Y,9^0/-
M*0D00 *DA4@D*1]6?\$UOA?XP^$G_!+GX8>$[_3Y/#OCG1?!T=D;348\&PO1
M&P02KSPK[21SQ7TE17'B<VQ&(I*E6?-9IW]%:WZON]295925F?F#\'_V8OBM
M\ =7\,ZMX#\ _$[2/$'B*\TFX^.,E]J%E.WB"XM[R*YN;[3+G[6&:::3[0CQ
MH%ADMIG!2.545OL;]KCX9>)IOB5\+?BIX.T*3Q5K'PUO;Z*\T%+J*UGU+3-0
MMQ#<_9VF98OM,;QV\B+(Z*RI(FY2X(]XHJ:^:5*M15)15U===4U9IZWVT79:
M= E4;=SY-^.Z_%;]K;PO]JT/X7WGA)?A_JND>+/#,7BO5+:VO/$.IV=YYDMH
M\-N\ZPV[V^^-99'#"616V;4W&U\19_'O[6_C[X<Q77PI\6^!O#/P]U]?&&LS
MZW>:=]KO[NT@F%K8626US,)-\\BL\SE$V1[06+G;]445G''<JM&"TO;?2ZL^
MOS]0Y_(I^']2FUG0;&\GLKC39[JWCFDM+@J9K5F4$QOM++N4G!VDC(."1S15
MRBN$S"O(/%>AP^$?C-X\\0WVF^)M4T.\\'0M>0VD5W?_ &IHI+D-;VL*;OWA
MCQ^ZA 9F?."SY/K]>=W'[1UEI?Q$UW0=4T'7-&M?#-@-6U/6KZ:QATNRL6^T
MA+IY/M.]8V-I/U3<NW+A <UM1YKOE[#Z6]/S3_0XGX"Z]+X*_9[\8Z]X?\+:
MQ:WUQ>3ZAIWA-M!O=+CT^8V\,<%E!%-#&=C,B/+)&OE"6:X8' )KRG3/!GQ
M^%6H>#?#7B9_%EG!X;U]]7_X2/PS9S^(V\B\TJ^6;=))9-^\;4%F=E\AA&EY
M H(!!'U[KOC/2_#5WI$%]?0VTVO7GV#3U8_\?<_E23>6OOY<,K?1#7BFC?\
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M^SA%XETKX^^((]:T>.>ZU"ZUR:^U6;P_=6]Q:P+J2_V;"NH2,8KF%[1U*Q1
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*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
